<!DOCTYPE html>
<html class="">
   <head>
      <meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
      <title>Pulmonary embolism - Treatment algorithm | BMJ Best Practice</title>
      <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
      <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
      <meta name="description" content="Pulmonary embolism (PE) is a life-threatening condition resulting from dislodged thrombi occluding the pulmonary vasculature; right heart failure and cardiac arrest may ensue if not aggressively treated. Symptoms include chest pain, dyspnoea, and a sense of apprehension. Haemoptysis and syncope a...">
      <!-- Optimize Page Hiding Snippet --> 
      <!-- <style>.async-hide
         { opacity: 0 !important}
      </style>
      <script async="" src="../js/adrum-ext.0086dbec5e8a6e717bf36d3a06b62042.js"></script><script src="../js/414393182248444" async=""></script><script async="" src="../js/fbevents.js"></script><script type="text/javascript" async="" src="../js/analytics.js"></script><script async="" src="../js/get-loader.js"></script><script type="text/javascript" async="" src="../js/insight.min.js"></script><script type="text/javascript" async="" src="../js/js"></script><script type="text/javascript" async="" src="../js/uwt.js"></script><script type="text/javascript" async="" src="../js/4896.js"></script><script type="text/javascript" async="" src="../js/analytics.js"></script><script async="" src="../js/gtm.js"></script><script>(function(a,s,y,n,c,h,i,d,e){s.className+=' '+y;h.start=1*new Date; h.end=i=function()
         {s.className=s.className.replace(RegExp(' ?'+y),'')}
         ; (a[n]=a[n]||[]).hide=h;setTimeout(function()
         
         {i();h.end=null}
         ,c);h.timeout=c;})(window,document.documentElement,'async-hide','dataLayer',3000,
         
         {'GTM-K3TZ3JV':true}
         );
      </script> -->
      <!-- end Optimize Page Hiding Snippet -->
      <!-- Google Tag Manager -->
      <!-- <script>
         /*<![CDATA[*/
         
          
         window.dataLayer = window.dataLayer || [];
         window.dataLayer.push({
                    'icsId': null,
                    'pi_icsId': "id82087",
                    'pi_icsName': "BMJ Group (Online access from BMA House)",
                    'access_rights': true,
                    'ics_groupings': [{"name":"Country Grouping"}],
                    'ics_countryName': "GB and ROW",
                    'siteLanguage': "en-gb",
                    'contentLanguage': "en-gb"
                 });
         		  
         /*]]>*/
            
      </script> -->
      <!-- <script>
         (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
         new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
         j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
         'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
         })(window,document,'script','dataLayer', 'GTM-K3TZ3JV');
      </script> -->
      <!-- End Google Tag Manager -->
      <!-- /* if user in China */ -->
      <link rel="stylesheet" type="text/css" media="screen" href="../css/material.css">
      <link rel="stylesheet" type="text/css" media="screen" href="../css/styles.css">
      <link rel="stylesheet" type="text/css" media="screen" href="../css/external.css">
      <link rel="shortcut icon" href="https://resources.bmj.com/repository/images/favicon.ico">
      <!-- <link rel="canonical" href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm">
      <link rel="alternate" hreflang="uk-ua" href="https://bestpractice.bmj.com/topics/uk-ua/116/treatment-algorithm">
      <link rel="alternate" hreflang="en-ie" href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm">
      <link rel="alternate" hreflang="az-az" href="https://bestpractice.bmj.com/topics/az-az/116/treatment-algorithm">
      <link rel="alternate" hreflang="en-us" href="https://bestpractice.bmj.com/topics/en-us/116/treatment-algorithm">
      <link rel="alternate" hreflang="ru" href="https://bestpractice.bmj.com/topics/ru-ru/116/treatment-algorithm">
      <link rel="alternate" hreflang="pt" href="https://bestpractice.bmj.com/topics/pt-br/116/treatment-algorithm">
      <link rel="alternate" hreflang="ka-ge" href="https://bestpractice.bmj.com/topics/ka-ge/116/treatment-algorithm">
      <link rel="alternate" hreflang="pt-br" href="https://bestpractice.bmj.com/topics/pt-br/116/treatment-algorithm">
      <link rel="alternate" hreflang="en" href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm">
      <link rel="alternate" hreflang="es-es" href="https://bestpractice.bmj.com/topics/es-es/116/treatment-algorithm">
      <link rel="alternate" hreflang="zh-cn" href="https://bestpractice.bmj.com/topics/zh-cn/116/treatment-algorithm">
      <link rel="alternate" hreflang="es" href="https://bestpractice.bmj.com/topics/es-es/116/treatment-algorithm">
      <link rel="alternate" hreflang="zh" href="https://bestpractice.bmj.com/topics/zh-cn/116/treatment-algorithm">
      <link rel="alternate" hreflang="x-default" href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm">
      <link rel="alternate" hreflang="ru-ru" href="https://bestpractice.bmj.com/topics/ru-ru/116/treatment-algorithm">
      <link rel="alternate" hreflang="vi" href="https://bestpractice.bmj.com/topics/vi-vn/116/treatment-algorithm">
      <link rel="alternate" hreflang="uk" href="https://bestpractice.bmj.com/topics/uk-ua/116/treatment-algorithm">
      <link rel="alternate" hreflang="ka" href="https://bestpractice.bmj.com/topics/ka-ge/116/treatment-algorithm">
      <link rel="alternate" hreflang="az" href="https://bestpractice.bmj.com/topics/az-az/116/treatment-algorithm">
      <link rel="alternate" hreflang="vi-vn" href="https://bestpractice.bmj.com/topics/vi-vn/116/treatment-algorithm">
      <link rel="alternate" hreflang="en-gb" href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm"> -->
      <!--[if lte IE 9]>
      <link rel="stylesheet" type="text/css" media="screen" href="/gzip_1791a8687c5480ce19e791d0825e7a6b/css/lte-ie-9.css" >
      <![endif]-->
      <!-- <script>
         /*<![CDATA[*/
           var appdynamics_app_key="AD-AAB-AAF-RGR";
         /*]]>*/
           	window["adrum-app-key"] = appdynamics_app_key;
           	window['adrum-start-time'] = new Date().getTime();
           
      </script>
      <script type="text/javascript" src="../js/appdynamics.js"></script> -->
      <script type="application/ld+json">
         [
         
         { "@context": "http://schema.org", "@type": "MedicalCondition" }
         ,{
         "isAccessibleForFree": "False",
         "hasPart":
         
         { "@type": "WebPageElement", "isAccessibleForFree": "False", "cssSelector" : ".gpw" }
         }]
      </script>
      <style></style>
   </head>
   <body class="gpw">
      <div role="dialog" aria-live="polite" aria-label="cookieconsent" aria-describedby="cookieconsent:desc" class="cc-window cc-banner cc-type-info cc-theme-classic cc-bottom cc-color-override--38786966 cc-invisible" style="display: none;">
         <!--googleoff: all--><span id="cookieconsent:desc" class="cc-message">We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our 
         <a aria-label="learn more about cookies" role="button" tabindex="0" class="cc-link" href="https://www.bmj.com/company/your-privacy/cookies-policy/" target="_blank">cookies policy</a></span>
         <div class="cc-compliance"><a aria-label="dismiss cookie message" role="button" tabindex="0" class="cc-btn cc-dismiss">OK!</a></div>
         <!--googleon: all-->
      </div>
      <!-- Google Tag Manager (noscript) -->
      <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-K3TZ3JV" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
      <!-- End Google Tag Manager (noscript) -->
      <!-- /* if user in China */ -->
      <header id="header" role="banner">
         <a class="sr-only" href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#sr-content">Skip to main content</a>
         <div class="bg-info text-white">
         </div>
         <nav id="globalNav" class="logo-img-mob navbar navbar-toggleable-md">
            <div class="container">
               <a href="https://bestpractice.bmj.com/" class="mobLogo"><span class="remove"><abbr>BMJ</abbr> Best Practice</span></a>
               <button class="navbar-toggler navbar-toggler-right" type="button" data-toggle="collapse" data-target="#navbarNav" aria-controls="navbarNav" aria-expanded="false" aria-label="Toggle navigation">
               <span class="material-icons"></span>
               </button>
               <div id="navbarNav" class="collapse navbar-collapse">
                  <ul id="globalNav-ul" class="navbar-nav" role="menubar">
                     <li id="globalNav-access" class="nav-item" role="presentation">
                        <span class="nav-link"> 
                        Access provided by: 
                        BMJ Group (Online access from BMA House)
                        </span>
                     </li>
                     <li id="globalNav-help" class="nav-item dropdown" role="menuitem">
                        <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" id="navbarDropdownMenuLink02" class="nav-link dropdown-toggle" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> 
                        Help <span class="states">
                        <span class="material-icons"></span>
                        <span class="material-icons"></span>
                        </span>
                        </a>
                        <div id="globalNav-help-options" class="dropdown-menu dropdown-menu-right" aria-labelledby="navbarDropdownMenuLink02">
                           <span class="material-icons"></span>
                           <ul role="menu">
                              <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/getting-started/" target="_blank">Getting started</a></li>
                              <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/faq/" target="_blank">FAQs</a></li>
                              <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/benefits-features/earn-cme-points/" target="_blank">About CME/CPD</a></li>
                              <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/contact-us/" target="_blank">Contact us</a></li>
                           </ul>
                        </div>
                     </li>
                     <li id="globalNav-register" class="nav-item">
                        <a href="https://bestpractice.bmj.com/registration" class="nav-link">Create account</a>
                     </li>
                     <li id="globalNav-login" class="nav-item">
                        <a href="https://bestpractice.bmj.com/login" class="nav-link">Log in</a>
                     </li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/recent-updates"><span class="icon icon-bp-icons-recent-updates"></span><span>Recent updates</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/specialties"><span class="icon icon-bp-icons-specialties"></span><span>Specialties</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/calculators"><span class="icon icon-bp-icons-calculators"></span><span>Calculators</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/patient-leaflets"><span class="icon icon-bp-icons-patient-leaflets"></span><span>Patient leaflets</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/procedural-videos"><span class="icon icon-bp-icons-procedural-videos"></span><span>Procedural videos</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/evidence"><span class="icon icon-bp-icons-evidence"></span><span>Evidence</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/drugs"><span class="icon icon-bp-icons-drugs"></span><span>Drugs</span></a></li>
                  </ul>
               </div>
            </div>
         </nav>
         <div id="mainSearch" class="container">
            <div class="row">
               <div class="col-lg-7">
                  <div class="logo-img"><a href="https://bestpractice.bmj.com/"><span class="remove"><abbr title="British Medical Journal">BMJ</abbr> Best Practice</span></a></div>
               </div>
               <div class="col-lg-5">
                  <style type="text/css">
                     #searchBoxWrap .tt-open:before {content: "Recently viewed topics:"; }
                     #searchBoxWrap .tt-label-override:before,
                     #searchBoxWrap .tt-suggested:before {content: "Suggested topics:" !important; }
                  </style>
                  <form id="searchBoxForm" action="https://bestpractice.bmj.com/search" role="search" novalidate="novalidate">
                     <div class="input-group">
                        <div id="searchBoxWrap">
                           <label for="q" class="sr-only">Search</label>
                           <span class="twitter-typeahead" style="position: relative; display: inline-block;">
                              <input id="q" type="text" name="q" placeholder="Search conditions, symptoms..." value="" class="tt-input" autocomplete="off" spellcheck="false" dir="auto" style="position: relative; vertical-align: top;">
                              <pre aria-hidden="true" style="position: absolute; visibility: hidden; white-space: pre; font-family: sans-serif; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 400; word-spacing: 0px; letter-spacing: 0px; text-indent: 0px; text-rendering: auto; text-transform: none;"></pre>
                              <div class="tt-menu" style="position: absolute; top: 100%; left: 0px; z-index: 100; display: none;">
                                 <div class="tt-dataset tt-dataset-0"></div>
                              </div>
                           </span>
                           <button id="mainSearchBtn" type="submit"><span class="material-icons"></span></button>
                        </div>
                     </div>
                  </form>
                  <script>
                     /*<![CDATA[*/
                     
                            // These are required in completion, see BP-232 -->
                            var searchDefaultLanguageCode = "en-gb";
                            var regionName = "GB and ROW";
                            var regionAvailableLanguagesCodes = [{"id":"1","code":"en-gb","displayName":"English"},{"id":"3","code":"pt-br","displayName":"Portugu\u00EAs"},{"id":"5","code":"es-es","displayName":"Espa\u00F1ol"},{"id":"7","code":"ru-ru","displayName":"\u0420\u0443\u0441\u0441\u043A\u0438\u0439"}];
                            var availableLanguages = [];
                     
                            for (i = 0; i < regionAvailableLanguagesCodes.length; i++) {
                                availableLanguages.push(regionAvailableLanguagesCodes[i].code);
                            }
                     /*]]>*/
                  </script>
               </div>
            </div>
         </div>
         <nav id="mainNav" class="navbar navbar-toggleable-md" role="navigation">
            <div class="container">
               <div id="mainNavbarNav">
                  <ul class="navbar-nav" role="menubar">
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/recent-updates"><span class="icon icon-bp-icons-recent-updates"></span><span>Recent updates</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/specialties"><span class="icon icon-bp-icons-specialties"></span><span>Specialties</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/calculators"><span class="icon icon-bp-icons-calculators"></span><span>Calculators</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/patient-leaflets"><span class="icon icon-bp-icons-patient-leaflets"></span><span>Patient leaflets</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/procedural-videos"><span class="icon icon-bp-icons-procedural-videos"></span><span>Procedural videos</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/evidence"><span class="icon icon-bp-icons-evidence"></span><span>Evidence</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/drugs"><span class="icon icon-bp-icons-drugs"></span><span>Drugs</span></a></li>
                  </ul>
               </div>
            </div>
         </nav>
      </header>
      <script type="text/javascript" id="">(function(){var f=google_tag_manager["GTM-K3TZ3JV"].macro(4),b=google_tag_manager["GTM-K3TZ3JV"].macro(5),a=function(a,b,d){var e="",c=new Date;d&&(c.setTime(c.getTime()+864E5*d),e="; expires\x3d"+c.toGMTString());document.cookie=a+"\x3d"+b+e+"; path\x3d/; domain\x3dbmj.com"};f?"true"!=b&&("justLoggedIn"==b?a("loggedIn","true",2):a("loggedIn","justLoggedIn",2)):a("loggedIn","false",2)})();</script>
      <main id="tmp" class="container tmp treatment-table more-pops main-container" role="main">
         <script type="text/javascript">
            /*<![CDATA[*/ 
            var topicId = 116; 
            var langCode="en-gb"; 
            /*]]>*/
         </script>
         <div id="topicNav" class="container">
            <div class="lang">
               <ul role="menu">
                  <li><a href="https://bestpractice.bmj.com/topics/en-gb/116" class="active">English</a></li>
                  <li><a href="https://bestpractice.bmj.com/topics/pt-br/116">Português</a></li>
                  <li><a href="https://bestpractice.bmj.com/topics/es-es/116">Español</a></li>
                  <li><a href="https://bestpractice.bmj.com/topics/ru-ru/116">Русский</a></li>
               </ul>
            </div>
            <div id="topicMenuTopBg" style="height: 110px;"></div>
            <div id="topicMenuTopWrap" style="height: 110px;">
               <div id="topicMenuTop" style="height: 110px;">
                  <h1>Pulmonary embolism</h1>
                  <div class="pdf-links-nav">
                     <div class="pdf">
                        <a href="https://bestpractice.bmj.com/topics/en-gb/116/pdf/116.pdf" target="_blank">
                        <span class="icon icon-bp-icons-pdf-extra-small-on-white"></span> <span>View PDF</span>
                        </a>
                     </div>
                  </div>
                  <div id="mobileMenu" class="mUp">
                     <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="button">
                     <span><span class="material-icons"></span> Menu</span>
                     <span><span class="material-icons"></span> Close</span>
                     </a>
                  </div>
                  <ul id="menuLinks" role="menu">
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#smenu-0" aria-owns="menu-0">Overview <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#smenu-1" aria-owns="menu-1">Theory <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#smenu-2" aria-owns="menu-2">Diagnosis <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#smenu-3" aria-owns="menu-3">Management <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#smenu-4" aria-owns="menu-4">Follow up <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#smenu-5" aria-owns="menu-5">Resources <span class="material-icons"></span><span class="material-icons"></span></a></li>
                  </ul>
               </div>
               <div id="como-2" class="card" style="display: none;">
                  <div class="card-block">
                      <div class="row">
                          <div class="col-md-3">
                             <span class="material-icons">
                             <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                           <g>
                              <g>
                                 <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                    c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                 <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                    c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                 <g>
                                    <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                 </g>
                              </g>
                              <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                 7.707,19.5 7.707,16 11.207,16 	"></polygon>
                           </g>
                           </svg>
                        </span> 
                        <b>Add comorbidities:</b></div>
                          <div class="col-md-6" id="comoselected-2">  </div>
                          <div class="col-md-2"><button class="btn" data-toggle="modal" data-target="#editComo">Edit</button></div>
                      </div> <!--- row --->
  
                  </div>
              </div>
            </div>
            <div id="topicMenuBottomWrap" style="height: 176px;">
               <nav id="topicMenuBottom" class="mUp" role="navigation" style="height: 176px;">
                  <ul id="menus" role="menubar">
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/116/criteria#" class="parent"><span>Overview</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-0">
                           <li><a href="116_overview_summary.html" id="Summary">Summary</a></li>
                        </ul>
                     </li>
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/116/criteria#" class="parent"><span>Theory</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-1">
                           <li><a href="116_theory_epidemiology.html" id="Epidemiology">Epidemiology</a></li>
                           <li><a href="116_theory_aetiology.html" id="Aetiology">Aetiology</a></li>
                           <li><a href="116_theory_case_history.html" id="Case history">Case history</a></li>
                        </ul>
                     </li>
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/116/criteria#" class="parent"><span>Diagnosis</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-2">
                           <li><a href="116_diagnosis_recommendations.html" id="Approach">Recommendations</a></li>
                           <li><a href="116_diagnosis_history-exam.html" id="History and exam">History and exam</a></li>
                           <li><a href="116_diagnosis_investigations.html" id="Investigations">Investigations</a></li>
                           <li><a href="116_diagnosis_differentials.html" id="Differentials">Differentials</a></li>
                           <li><a href="116_diagnosis_criteria.html" id="Criteria">Criteria</a></li>
                        </ul>
                     </li>
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/116/criteria#" class="parent"><span>Management</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-3">
                           <li><a href="116_management_recommendations.html" id="Approach">Recommendations</a></li>
                           <li><a href="116_management_treatment_algorithm.html" id="Treatment algorithm" class="active">Treatment algorithm</a></li>
                           <li><a href="116_management_emerging.html" id="Emerging">Emerging</a></li>
                           <li><a href="116_management_prevention.html" id="Prevention">Prevention</a></li>
                           <li><a href="116_management_patient_discussions.html" id="Patient discussions">Patient discussions</a></li>
                        </ul>
                     </li>
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/116/criteria#" class="parent"><span>Follow up</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-4">
                           <li><a href="116_follow_up_monitoring.html" id="Monitoring">Monitoring</a></li>
                           <li><a href="116_follow_up_complications.html" id="Complications">Complications</a></li>
                           <li><a href="116_follow_up_prognosis.html" id="Prognosis">Prognosis</a></li>
                        </ul>
                     </li>
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/116/criteria#" class="parent"><span>Resources</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-5">
                           <li><a href="116_resources_guidelines.html" id="Guidelines">Guidelines</a></li>
                           <li><a href="116_resources_images_videos.html" id="Images and videos">Images and videos</a></li>
                           <li><a href="116_resources_references.html" id="References">References</a></li>
                           <li><a href="116_resources_patient_leaflets.html" id="Patient leaflets">Patient leaflets</a></li>
                           <li><a href="116_resources_evidence.html" id="Evidence">Evidence</a></li>
                        </ul>
                     </li>
                     <li class="mpdf"><a href="https://bestpractice.bmj.com/topics/en-gb/116/pdf/116.pdf" target="_blank"><span class="icon icon-bp-icons-pdf-extra-small-on-white"></span> <span>View PDF</span></a></li>
                  </ul>
               </nav>
            </div>
         </div>
         <h2 id="sr-content">Treatment algorithm</h2>
         <p class="w-75">Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: <a href="https://bestpractice.bmj.com/info/disclaimer/" target="_blank">see disclaimer</a></p>
         <div id="como-1" class="card">
            <div class="card-block">
               <div class="row">
                  <div class="col-md-3"><span class="material-icons">
                     <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                     <g>
                        <g>
                           <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                              c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                           <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                              c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                           <g>
                              <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                           </g>
                        </g>
                        <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                           7.707,19.5 7.707,16 11.207,16 	"></polygon>
                     </g>
                     </svg>
                  </span> <b>Add comorbidities:</b></div>
                  <div class="col-md-6" id="comoselected-1">  <button class="btn" data-toggle="modal" data-target="#editComo">Edit</button></div>
               </div>
               <!--- row --->
            </div>
         </div>
         
         <div id="poce_contents" class="treatment-algorithm">
            <div class="card">
               <div class="card-block">
                  <div class="container">
                     <div class="rowHead" id="acute">
                        <div class="col-md-12">
                           ACUTE
                        </div>
                     </div>
                     <div class="panel">
                        <div class="panel-heading">
                           <h3>
                              <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" id="patientGroup-0-0">
                              <span>high risk (massive PE or high clinical probability of PE with shock or hypotension [i.e., systolic BP &lt;90 mmHg]), no contraindication to anticoagulation or thrombolysis</span>
                              <span class="hidden-sm-down">
                              <span class="msg">VIEW ALL</span>
                              <span class="material-icons" role="button"><span></span><span></span></span>
                              </span>
                              </a>
                           </h3>
                        </div>
                        <!--/.panel-heading -->
                        <div class="panel-body">
                           <section class="panel-group">
                              <div class="panel-header">
                                 <p class="panel-title"> 
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_0" aria-controls="panel_0_0_0" aria-expanded="false">
                                    <span class="titles-wrap col-md-12">
                                    <span class="title-02">
                                    <span class="title-03 col-md-1">
                                    1st line
                                    <span class="noShow">&nbsp;–&nbsp;</span>
                                    </span>
                                    <span class="title-04">
                                    <span class="material-icons"><span></span><span></span></span>
                                    <span class="txtwrap no-icon">
                                       respiratory support
                                       <span class="material-icons">
                                          <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                          <g>
                                             <g>
                                                <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                   c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                   c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                <g>
                                                   <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                </g>
                                             </g>
                                             <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                          </g>
                                          </svg>
                                       </span>                                    
                                    </span>
                                    </span>
                                    </span>
                                    </span>
                                    </a>
                                 </p>
                              </div>
                              <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_0_0" id="panel_0_0_0" aria-expanded="false">
                                 <!--  ADJUNCT/PLUS DISCLAIMER -->
                                 <!--/.treatment-wrap-->
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Supplemental high-concentration oxygen should be administered, targeting oxygen saturations of 94% to 98% (or 88% to 92% in patients at risk of hypercapnic respiratory failure).
                                    <span class="reference"> 
                                    <a href="#referencePop213" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[213]</a> 
                                    <span class="citationText" aria-hidden="true">O'Driscoll BR, Howard LS, Earis J, et al; British Thoracic Society Emergency Oxygen Guideline Group; BTS Emergency Oxygen Guideline Development Group. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax. 2017 Jun;72(Suppl 1):ii1-90.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://www.brit-thoracic.org.uk/document-library/clinical-information/oxygen/2017-emergency-oxygen-guideline/bts-guideline-for-oxygen-use-in-adults-in-healthcare-and-emergency-settings/
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/28507176?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Intubation and mechanical ventilation may be necessary for patients with severe hypoxaemia/respiratory failure. Mechanical ventilation can lead to hypotension, so blood pressure (BP) should be monitored closely.
                                 </p>

                                 <div id="hypertension-como-content" style="display: none;">
                                       
                                    
                                       <div id="poce_drug_msg">
                                             <span class="material-icons">
                                                   <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                      <g>
                                                         <g>
                                                            <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                               c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                            <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                               c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                            <g>
                                                               <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                            </g>
                                                         </g>
                                                         <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                            7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                      </g>
                                                      </svg>
                                             </span> 
                                             <h3 class="poce_title">
                                                   Drug choice, dose and interactions may be affected by the patient's comorbidities. Check your local drug formulary.
                                                </h3>
                                                <h3>Sub title h3</h3>
                                                <p>Lorem ipsum dolor sit amet consectetur adipisicing elit. Ea perferendis sit veritatis, id eum voluptatem pariatur ipsum, repellat sapiente provident cum eius aspernatur vero nulla ut nisi, doloribus nobis blanditiis!</p>
                                                <ul>
                                                   <li>list item</li>
                                                   <li>list item</li>
                                                   <li>list item</li>
                                                   <li>list item</li>
                                                </ul>
                                          </div>

                                 </div>
                              </div>
                              <!--/.panel-body -->
                           </section>
                           <section class="panel-group">
                              <div class="panel-header">
                                 <p class="panel-title"> 
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_1" aria-controls="panel_0_0_1" aria-expanded="false">
                                    <span class="titles-wrap col-md-12">
                                    <span class="title-02">
                                    <span class="title-03 col-md-1">
                                    Plus
                                    <span class="noShow">&nbsp;–&nbsp;</span>
                                    </span>
                                    <span class="title-04">
                                    <span class="material-icons"><span></span><span></span></span>
                                    <span class="txtwrap no-icon">intravenous fluids</span>
                                    </span>
                                    </span>
                                    </span>
                                    </a>
                                 </p>
                              </div>
                              <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_0_1" id="panel_0_0_1" aria-expanded="false">
                                 <!--  ADJUNCT/PLUS DISCLAIMER -->
                                 <p class="w-75 smPopTxt">Treatment recommended for ALL patients in selected patient group</p>
                                 <!--/.treatment-wrap-->
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    If systolic BP is &lt;90 mmHg, intravenous fluids should be given. Acute right ventricular failure with resulting low systemic output is the leading cause of death in patients with PE.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Studies indicate that aggressive volume expansion is of no benefit, and may even worsen right ventricular function by causing mechanical overstretch, or by reflex mechanisms that depress contractility. However, modest fluid challenge (i.e., 500 mL) may be of benefit in patients with PE, a low cardiac index, and normal BP.
                                    <span class="reference"> 
                                    <a href="#referencePop168" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[168]</a> 
                                    <span class="citationText" aria-hidden="true">Mercat A, Diehl JL, Meyer G, et al. Hemodynamic effects of fluid loading in acute massive pulmonary embolism. Crit Care Med. 1999 Mar;27(3):540-4.</span> 
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/10199533?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                              </div>
                              <!--/.panel-body -->
                           </section>
                           <section class="panel-group">
                              <div class="panel-header">
                                 <p class="panel-title"> 
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_2" aria-controls="panel_0_0_2" aria-expanded="false">
                                    <span class="titles-wrap col-md-12">
                                    <span class="title-02">
                                    <span class="title-03 col-md-1">
                                    Plus
                                    <span class="noShow">&nbsp;–&nbsp;</span>
                                    </span>
                                    <span class="title-04">
                                    <span class="material-icons"><span></span><span></span></span>
                                    <span class="txtwrap no-icon">
                                       vasoactive agents
                                       <span class="material-icons">
                                          <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                          <g>
                                             <g>
                                                <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                   c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                   c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                <g>
                                                   <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                </g>
                                             </g>
                                             <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                          </g>
                                          </svg>
                                       </span>
                                    </span>
                                    </span>
                                    </span>
                                    </span>
                                    </a>
                                 </p>
                              </div>
                              <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_0_2" id="panel_0_0_2" aria-expanded="false">
                                 <!--  ADJUNCT/PLUS DISCLAIMER -->
                                 <p class="w-75 smPopTxt">Treatment recommended for ALL patients in selected patient group</p>
                                 <div class="treatment-wrap">
                                    <!-- display regimens -->
                                    <div class="treatment-box-cplus mt-4">
                                    <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                       <h4>Primary options</h4>
                                       <div id="cad-como-content" style="display: none;">
                                          <div id="poce_drug_msg">
                                             <span class="material-icons">
                                                   <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                                      <g>
                                                         <g>
                                                            <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                                               c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                                            <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                                               c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                                            <g>
                                                               <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                                            </g>
                                                         </g>
                                                         <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                                            7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                                      </g>
                                                      </svg>
                                             </span> 
                                             <h3 class="poce_title">
                                                   Drug choice, dose and interactions may be affected by the patient's comorbidities. Check your local drug formulary.
                                                </h3>
                                                <h3>Sub title h3</h3>
                                                <p>Lorem ipsum dolor sit amet consectetur adipisicing elit. Ea perferendis sit veritatis, id eum voluptatem pariatur ipsum, repellat sapiente provident cum eius aspernatur vero nulla ut nisi, doloribus nobis blanditiis!</p>
                                                <ul>
                                                   <li>list item</li>
                                                   <li>list item</li>
                                                   <li>list item</li>
                                                   <li>list item</li>
                                                </ul>
                                          </div>
                                       </div>

                                       <p>
                                          <a href="#drugDbPop_b3fb3286-271c-47f6-ae52-1bd3958b1e9b_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">adrenaline (epinephrine)</a><span>: </span><span>2-10 micrograms/minute by intravenous infusion initially, adjust dose according to response</span>
                                       </p>
                                       <p class="small-or">OR</p>
                                       <p>
                                          <a href="#drugDbPop_46d9672e-3313-452d-9bfd-a4ddf90b32f3_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">noradrenaline (norepinephrine)</a><span>: </span><span>0.4 to 0.8 mg/hour by intravenous infusion initially, adjust dose according to response | MORE:  Dose refers to noradrenaline base</span>
                                       </p>
                                       <p class="small-or">OR</p>
                                       <p>
                                          <a href="#drugDbPop_a37dcf97-a50b-4776-ad01-6fd4a31bb295_en-gb" data-trigger="click focus" class="drugDbPop"   data-toggle="popover" data-original-title="" title="">dobutamine</a><span>: </span><span>2.5 to 10 micrograms/kg/minute by intravenous infusion initially, adjust dose according to response, maximum 40 micrograms/kg/minute</span>
                                       </p>

                                       <p class="como_link mt-4"><a href="#">&#9664; Show drug doses for a patient with no comorbidities</a></p>


                                    </div>
                                    
                                       
                                    
                                
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    If systolic BP is &lt;90 mmHg, vasopressors may be given in parallel with (or while waiting for) pharmacological, surgical, or interventional re-perfusion treatment.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Noradrenaline (norepinephrine) may improve right ventricular function and right ventricular coronary perfusion.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;Its use should probably be limited to hypotensive patients.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Dobutamine enhances contractility with an increase in stroke volume and cardiac output. However, its systemic vasodilatory effect can lead to hypotension.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Adrenaline (epinephrine) combines the beneficial properties of noradrenaline (norepinephrine) (vasoconstriction with increased right ventricular perfusion, positive inotropy) and dobutamine (positive inotropy), but without the vasodilatory effects associated with the latter.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop214" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[214]</a> 
                                    <span class="citationText" aria-hidden="true">Layish DT, Tapson VF. Pharmacologic hemodynamic support in massive pulmonary embolism. Chest. 1997 Jan;111(1):218-24.</span> 
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/8996020?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                              
                              <!--/.panel-body -->
                           </section>
                           <section class="panel-group">
                              <div class="panel-header">
                                 <p class="panel-title"> 
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_3" aria-controls="panel_0_0_3" aria-expanded="false">
                                    <span class="titles-wrap col-md-12">
                                    <span class="title-02">
                                    <span class="title-03 col-md-1">
                                    Plus
                                    <span class="noShow">&nbsp;–&nbsp;</span>
                                    </span>
                                    <span class="title-04">
                                    <span class="material-icons"><span></span><span></span></span>
                                    <span class="txtwrap no-icon">anticoagulation</span>
                                    </span>
                                    </span>
                                    </span>
                                    </a>
                                 </p>
                              </div>
                              <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_0_3" id="panel_0_0_3" aria-expanded="false">
                                 <!--  ADJUNCT/PLUS DISCLAIMER -->
                                 <p class="w-75 smPopTxt">Treatment recommended for ALL patients in selected patient group</p>
                                 <div class="treatment-wrap">
                                    <!-- display regimens -->
                                    <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                    <h4>Primary options</h4>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">heparin</a><span>: </span><span>80 units/kg intravenous bolus initially, followed by 18 units/kg/hour intravenous infusion, adjust dose according to aPTT; 333 units/kg subcutaneously initially, followed by 250 units/kg every 12 hours</span>
                                       </p>
                                       <p class="small-or">and</p>
                                       <p>
                                          <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">warfarin</a><span>: </span><span>5 mg orally once daily initially, adjust according to INR (goal INR is 2 to 3)</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                 </div>
                                 <div class="treatment-wrap">
                                    <!-- display regimens -->
                                    <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                    <h4>Secondary options</h4>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_0f8c4ada-cd84-4c04-8860-01a81e07c1f9_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">rivaroxaban</a><span>: </span><span>15 mg orally twice daily initially for 3 weeks, followed by 20 mg once daily</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                    <p class="small-or">OR</p>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_aff9d94e-1579-4f56-acb7-73775d12d818_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">apixaban</a><span>: </span><span>10 mg orally twice daily for 7 days, followed by 5 mg twice daily</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                    <p class="small-or">OR</p>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_6402d40a-aa86-4def-a6af-9d56b0e8ef3e_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dabigatran</a><span>: </span><span>150 mg orally twice daily, starting 5-10 days after treatment with a parenteral anticoagulant</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                    <p class="small-or">OR</p>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_4b33f194-29da-4239-aae9-c1746e2bda94_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">edoxaban</a><span>: </span><span>body weight ≤60 kg: 30 mg orally once daily, starting 5-10 days after treatment with a parenteral anticoagulant; body weight &gt;60 kg: 60 mg orally once daily, starting 5-10 days after treatment with a parenteral anticoagulant</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                 </div>
                                 <div class="treatment-wrap">
                                    <!-- display regimens -->
                                    <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                    <h4>Tertiary options</h4>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_3984222a-c42a-4f8a-bff1-f99645ade85d_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">enoxaparin</a><span>: </span><span>1 mg/kg subcutaneously twice daily; or 1.5 mg/kg subcutaneously once daily</span>
                                       </p>
                                       <p class="small-or">and</p>
                                       <p>
                                          <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">warfarin</a><span>: </span><span>5 mg orally once daily initially, adjust according to INR (goal INR is 2 to 3)</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                    <p class="small-or">OR</p>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_d4ccd444-8501-447d-848f-bc97c03774ba_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dalteparin</a><span>: </span><span>200 units/kg subcutaneously once daily, maximum 18,000 units/dose; or 100 units/kg subcutaneously twice daily</span>
                                       </p>
                                       <p class="small-or">and</p>
                                       <p>
                                          <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">warfarin</a><span>: </span><span>5 mg orally once daily initially, adjust according to INR (goal INR is 2 to 3)</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                    <p class="small-or">OR</p>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_a4adb6a6-1e28-4057-9789-361aa3c914b8_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">fondaparinux</a><span>: </span><span>body weight &lt;50 kg: 5 mg subcutaneously once daily; body weight 50-100 kg: 7.5 mg subcutaneously once daily; body weight &gt;100 kg: 10 mg subcutaneously once daily</span>
                                       </p>
                                       <p class="small-or">and</p>
                                       <p>
                                          <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">warfarin</a><span>: </span><span>5 mg orally once daily initially, adjust according to INR (goal INR is 2 to 3)</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                 </div>
                                 <!--/.treatment-wrap-->
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Patients who present with suspected PE should receive an anticoagulant in the acute phase (the initial 10-day period following PE diagnosis), unless contraindicated.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;If PE is subsequently excluded, anticoagulation can be discontinued. In patients with confirmed PE, anticoagulation should continue for at least 3 months.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop101" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[101]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Barco S, Lankeit M, et al. Management of pulmonary embolism: an update. J Am Coll Cardiol. 2016 Mar 1;67(8):976-90.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://www.onlinejacc.org/content/67/8/976
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26916489?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;Acute-phase parenteral anticoagulation (unfractionated heparin [UFH], low molecular weight heparin [LMWH], or fondaparinux) should overlap with the initiation of a vitamin K antagonist (VKA). 
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Parenteral anticoagulation with UFH for a minimum of 5 days is the preferred acute-phase treatment for patients with high-risk PE (in whom primary re-perfusion [i.e., systemic thrombolytic therapy or embolectomy] is considered).
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;Parenteral UFH can be stopped once a therapeutic international normalised ratio (INR) of 2.0 to 3.0 has been established.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop101" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[101]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Barco S, Lankeit M, et al. Management of pulmonary embolism: an update. J Am Coll Cardiol. 2016 Mar 1;67(8):976-90.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://www.onlinejacc.org/content/67/8/976
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26916489?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;UFH has a short half-life, is easy to monitor, and is readily reversed by protamine.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    The direct-acting oral anticoagulants rivaroxaban and apixaban may be prescribed without the need for pre-treatment with a parenteral anticoagulant. However, both dabigatran and edoxaban require lead-in therapy with a parenteral anticoagulant for 5 to 10 days. One meta-analysis found that direct-acting oral anticoagulants have similar efficacy to a heparin/VKA regimen, but with reduced risk of major bleeding (relative risk 0.61, 95% CI 0.21 to 0.68).
                                    <span class="reference"> 
                                    <a href="#referencePop101" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[101]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Barco S, Lankeit M, et al. Management of pulmonary embolism: an update. J Am Coll Cardiol. 2016 Mar 1;67(8):976-90.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://www.onlinejacc.org/content/67/8/976
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26916489?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop215" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[215]</a> 
                                    <span class="citationText" aria-hidden="true">van Es N, Coppens M, Schulman S, et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014 Sep 18;124(12):1968-75.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://www.bloodjournal.org/content/124/12/1968.long
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/24963045?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;Furthermore, direct-acting oral anticoagulants do not require monitoring, have a rapid onset of action, and are short-acting. They do not interact with food, but they can interact with other pharmacotherapeutic agents. Dabigatran can be reversed with idarucizumab. Andexanet alfa is approved by the US Food and Drug Administration (FDA) for the reversal of apixaban- and rivaroxaban-mediated anticoagulation in patients with life-threatening or uncontrolled bleeding. At present there is no approved reversal agent for edoxaban. 
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    European guidelines recommend UFH for obese patients, and for patients with severe renal impairment (creatinine clearance &lt;30 mL/minute).
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;The American College of Chest Physicians recommends a VKA for patients with severe renal impairment.
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    LMWH is the preferred agent for initial anticoagulation in patients with active cancer, or hepatic impairment and coagulopathy.
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" data-trigger="click focus" data-toggle="popover" class="cochranePop" data-original-title="" title="">
                                    [ <img src="../images/cca-cochrane-logo-inline.png" alt="Cochrane Clinical Answers logo"> ] 
                                    </a>
                                    <span class="ccaTitle" aria-hidden="true">How do low‐molecular‐weight heparin (LMWH), vitamin K agonists (VKAs), and direct oral anticoagulants (DOACs) compare for treatment of venous thromboembolism (VTE) in people with cancer?</span>
                                    <span class="ccaUrl" aria-hidden="true">/cca.html?targetUrl=https://cochranelibrary.com/cca/doi/10.1002/cca.2255/full</span>
                                    <span class="ccaHrefText" aria-hidden="true">Show me the answer</span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Health professionals should refer to the label and/or local formularies before prescribing a direct-acting oral anticoagulant for a patient with renal or hepatic impairment.
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Fondaparinux carries a low risk of inducing heparin-induced thrombocytopenia (HIT) and appears to be effective for patients with suspected or confirmed HIT.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop216" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[216]</a> 
                                    <span class="citationText" aria-hidden="true">Kang M, Alahmadi M, Sawh S, et al. Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study. Blood. 2015 Feb 5;125(6):924-9.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://www.bloodjournal.org/content/125/6/924.long
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25515959?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;It is contraindicated in patients with severe renal impairment.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    LMWH is recommended for women who are pregnant (weight-adjusted dose, consult specialist for guidance) or who may be pregnant.
                                    <span class="reference"> 
                                    <a href="#referencePop36" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[36]</a> 
                                    <span class="citationText" aria-hidden="true">Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(2 Suppl):e691S-736S.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(12)60136-6/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/22315276?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;It does not cross the placenta, and routine monitoring is not generally required.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop212" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[212]</a> 
                                    <span class="citationText" aria-hidden="true">Royal College of Obstetricians and Gynaecologists. Reducing the risk of venous thromboembolism during pregnancy and the puerperium. Green-top guideline No. 37a. Apr 2015 [internet publication].</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://www.rcog.org.uk/globalassets/documents/guidelines/gtg-37a.pdf
                                    </span>
                                    </span>
                                    &nbsp;Other anticoagulants, including VKAs, may cross the placenta.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>

                                    <div id="copd-como-content" style="display: none;">
                                          <p>The standard Lorem Ipsum passage, used since the 1500s
                                             "Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum."</p>
                                             
                                          <p>Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC
                                             "Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?"</p>
      
                                    </div>
                                    
                                 </p>
                              </div>
                              <!--/.panel-body -->
                           </section>
                           <section class="panel-group">
                              <div class="panel-header">
                                 <p class="panel-title"> 
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_4" aria-controls="panel_0_0_4" aria-expanded="false">
                                    <span class="titles-wrap col-md-12">
                                    <span class="title-02">
                                    <span class="title-03 col-md-1">
                                    Plus
                                    <span class="noShow">&nbsp;–&nbsp;</span>
                                    </span>
                                    <span class="title-04">
                                    <span class="material-icons"><span></span><span></span></span>
                                    <span class="txtwrap no-icon">thrombolysis or embolectomy or catheter-directed therapy</span>
                                    </span>
                                    </span>
                                    </span>
                                    </a>
                                 </p>
                              </div>
                              <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_0_4" id="panel_0_0_4" aria-expanded="false">
                                 <!--  ADJUNCT/PLUS DISCLAIMER -->
                                 <p class="w-75 smPopTxt">Treatment recommended for ALL patients in selected patient group</p>
                                 <div class="treatment-wrap">
                                    <!-- display regimens -->
                                    <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                    <h4>Primary options</h4>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_89dc308c-7daa-4c1f-a0c4-829a581f1936_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">alteplase</a><span>: </span><span>100 mg intravenously given over 2 hours</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                    <p class="small-or">OR</p>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_88583afa-6bbd-4755-a21e-c63ab12370f0_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">reteplase</a><span>: </span><span>10 units intravenously initially, followed by second dose of 10 units 30 minutes later</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                 </div>
                                 <!--/.treatment-wrap-->
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Systemic thrombolytic therapy is recommended in patients with haemodynamic compromise (shock or systolic BP &lt;90 mmHg), as this patient group has a high mortality rate.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop101" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[101]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Barco S, Lankeit M, et al. Management of pulmonary embolism: an update. J Am Coll Cardiol. 2016 Mar 1;67(8):976-90.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://www.onlinejacc.org/content/67/8/976
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26916489?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop173" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[173]</a> 
                                    <span class="citationText" aria-hidden="true">Hao Q, Dong BR, Yue J, et al. Thrombolytic therapy for pulmonary embolism. Cochrane Database Syst Rev. 2015 Sep 30;(9):CD004437.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD004437.pub4/full
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26419832?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop174" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[174]</a> 
                                    <span class="citationText" aria-hidden="true">Chatterjee S, Chakraborty A, Weinberg I, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA. 2014 Jun 18;311(23):2414-21.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://jamanetwork.com/journals/jama/fullarticle/1881311
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/24938564?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Systemic thrombolytic therapy is associated with lower all-cause mortality than anticoagulation alone in patients with massive PE (acute PE with sustained hypotension [i.e., systolic BP &lt;90 mmHg for at least 15 minutes]).
                                    <span class="reference"> 
                                    <a href="#referencePop173" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[173]</a> 
                                    <span class="citationText" aria-hidden="true">Hao Q, Dong BR, Yue J, et al. Thrombolytic therapy for pulmonary embolism. Cochrane Database Syst Rev. 2015 Sep 30;(9):CD004437.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD004437.pub4/full
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26419832?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop174" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[174]</a> 
                                    <span class="citationText" aria-hidden="true">Chatterjee S, Chakraborty A, Weinberg I, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA. 2014 Jun 18;311(23):2414-21.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://jamanetwork.com/journals/jama/fullarticle/1881311
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/24938564?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop217" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[217]</a> 
                                    <span class="citationText" aria-hidden="true">Marti C, John G, Konstantinides S, et al. Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. Eur Heart J. 2015 Mar 7;36(10):605-14.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/36/10/605/514452
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/24917641?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;Thrombolysis is, however, associated with a significantly increased risk of major bleeding.
                                    <span class="reference"> 
                                    <a href="#referencePop173" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[173]</a> 
                                    <span class="citationText" aria-hidden="true">Hao Q, Dong BR, Yue J, et al. Thrombolytic therapy for pulmonary embolism. Cochrane Database Syst Rev. 2015 Sep 30;(9):CD004437.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD004437.pub4/full
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26419832?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop174" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[174]</a> 
                                    <span class="citationText" aria-hidden="true">Chatterjee S, Chakraborty A, Weinberg I, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA. 2014 Jun 18;311(23):2414-21.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://jamanetwork.com/journals/jama/fullarticle/1881311
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/24938564?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop217" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[217]</a> 
                                    <span class="citationText" aria-hidden="true">Marti C, John G, Konstantinides S, et al. Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. Eur Heart J. 2015 Mar 7;36(10):605-14.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/36/10/605/514452
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/24917641?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Absolute contraindications to thrombolysis include: haemorrhagic stroke or stroke of unknown origin at any time; ischaemic stroke in the preceding 6 months; central nervous system damage or neoplasms; recent major trauma/surgery/head injury (in the preceding 3 weeks); gastrointestinal bleeding within the last month; known bleeding risk.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop177" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[177]</a> 
                                    <span class="citationText" aria-hidden="true">Van de Werf F, Ardissino D, Betriu A, et al; task force on the management of acute myocardial infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2003 Jan;24(1):28-66.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/24/1/28/562262
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/12559937?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Surgical pulmonary embolectomy and catheter-directed therapy have lower attendant bleeding risk than systemic therapy and may, therefore, be considered in high-risk patients unable to receive thrombolytic therapy because of bleeding risk, or when there is insufficient time for effective systemic thrombolytic therapy, or when such therapy has failed.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop179" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[179]</a> 
                                    <span class="citationText" aria-hidden="true">Dolovich LR, Ginsberg JS, Douketis JD, et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med. 2000 Jan 24;160(2):181-8.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/485206
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/10647756?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop184" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[184]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Barco S. Systemic thrombolytic therapy for acute pulmonary embolism: who is a candidate? Semin Respir Crit Care Med. 2017 Feb;38(1):56-65.</span> 
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/28208199?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Surgical pulmonary embolectomy is recommended for patients in whom systemic thrombolytic therapy has failed or is absolutely contraindicated.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Catheter-directed therapy, which typically involves a combination of mechanical and pharmacotherapeutic thrombus fragmentation, may be considered for patients in whom full-dose systemic thrombolytic therapy has failed.
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;Catheter-directed therapy uses a lower dose of thrombolytic drug (approximately one third of full-dose systemic thrombolytic therapy) and is believed to reduce the risks of bleeding at remote sites (for example, intracranially or gastrointestinally).
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                              </div>
                              <!--/.panel-body -->
                           </section>
                           <section class="panel-group">
                              <div class="panel-header">
                                 <p class="panel-title"> 
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_0_5" aria-controls="panel_0_0_5" aria-expanded="false">
                                    <span class="titles-wrap col-md-12">
                                    <span class="title-02">
                                    <span class="title-03 col-md-1">
                                    Adjunct
                                    <span class="noShow">&nbsp;–&nbsp;</span>
                                    </span>
                                    <span class="title-04">
                                    <span class="material-icons"><span></span><span></span></span>
                                    <span class="txtwrap no-icon">venous filter</span>
                                    </span>
                                    </span>
                                    </span>
                                    </a>
                                 </p>
                              </div>
                              <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_0_5" id="panel_0_0_5" aria-expanded="false">
                                 <!--  ADJUNCT/PLUS DISCLAIMER -->
                                 <p class="w-75 smPopTxt">Treatment recommended for SOME patients in selected patient group</p>
                                 <!--/.treatment-wrap-->
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    An inferior vena cava (IVC) filter can be placed in patients experiencing a major bleeding event during the acute phase.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop184" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[184]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Barco S. Systemic thrombolytic therapy for acute pulmonary embolism: who is a candidate? Semin Respir Crit Care Med. 2017 Feb;38(1):56-65.</span> 
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/28208199?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;Some centres insert IVC filters intraoperatively or immediately postoperatively in patients who undergo surgical pulmonary embolectomy.
                                    <span class="reference"> 
                                    <a href="#referencePop185" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[185]</a> 
                                    <span class="citationText" aria-hidden="true">Leacche M, Unic D, Goldhaber SZ, et al. Modern surgical treatment of massive pulmonary embolism: Results in 47 consecutive patients after rapid diagnosis and aggressive surgical approach. J Thorac Cardiovasc Surg. 2005 May;129(5):1018-23.</span> 
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/15867775?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop218" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[218]</a> 
                                    <span class="citationText" aria-hidden="true">Aklog L, Williams CS, Byrne JG, et al. Acute pulmonary embolectomy: a contemporary approach. Circulation. 2002 Mar 26;105(12):1416-9.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://circ.ahajournals.org/content/105/12/1416.long
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/11914247?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop219" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[219]</a> 
                                    <span class="citationText" aria-hidden="true">Greelish JP, Leacche M, Solenkova NS, et al. Improved midterm outcomes for type A (central) pulmonary emboli treated surgically. J Thorac Cardiovasc Surg. 2011 Dec;142(6):1423-9.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://www.jtcvs.org/article/S0022-5223(11)00280-7/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/21481423?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Observational studies suggest that insertion of a venous filter might reduce PE-related mortality rates in the acute phase but with an associated increase in the risk of filter-related venous thromboembolism.
                                    <span class="reference"> 
                                    <a href="#referencePop190" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[190]</a> 
                                    <span class="citationText" aria-hidden="true">Stein PD, Matta F, Keyes DC, et al. Impact of vena cava filters on in-hospital case fatality rate from pulmonary embolism. Am J Med. 2012 May;125(5):478-84.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://www.amjmed.com/article/S0002-9343(11)00481-5/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/22310013?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop191" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[191]</a> 
                                    <span class="citationText" aria-hidden="true">Muriel A, Jiménez D, Aujesky D, et al. Survival effects of inferior vena cava filter in patients with acute symptomatic venous thromboembolism and a significant bleeding risk. J Am Coll Cardiol. 2014 Apr 29;63(16):1675-83.</span> 
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/24576432?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Complications associated with permanent IVC filters are common, although they are rarely fatal.
                                    <span class="reference"> 
                                    <a href="#referencePop191" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[191]</a> 
                                    <span class="citationText" aria-hidden="true">Muriel A, Jiménez D, Aujesky D, et al. Survival effects of inferior vena cava filter in patients with acute symptomatic venous thromboembolism and a significant bleeding risk. J Am Coll Cardiol. 2014 Apr 29;63(16):1675-83.</span> 
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/24576432?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;Overall, early complications (including insertion-site thrombosis) occur in approximately 10% of patients. Late complications are more frequent and include recurrent DVT (approximately 20% of patients) and post-thrombotic syndrome (up to 40% of patients).
                                    <span class="reference"> 
                                    <a href="#referencePop192" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[192]</a> 
                                    <span class="citationText" aria-hidden="true">Rajasekhar A, Streiff MB. Vena cava filters for management of venous thromboembolism: a clinical review. Blood Rev. 2013 Sep;27(5):225-41.</span> 
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/23932118?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop193" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[193]</a> 
                                    <span class="citationText" aria-hidden="true">PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prévention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation. 2005 Jul 19;112(3):416-22.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://circ.ahajournals.org/content/112/3/416.long
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/16009794?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;Occlusion of the IVC affects approximately 22% of patients at 5 years and 33% at 9 years, regardless of the use and duration of anticoagulation.
                                    <span class="reference"> 
                                    <a href="#referencePop193" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[193]</a> 
                                    <span class="citationText" aria-hidden="true">PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prévention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation. 2005 Jul 19;112(3):416-22.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://circ.ahajournals.org/content/112/3/416.long
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/16009794?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Post-filter anticoagulation should be considered on a case-by-case basis according to relative and absolute contraindications.
                                    <span class="reference"> 
                                    <a href="#referencePop194" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[194]</a> 
                                    <span class="citationText" aria-hidden="true">Decousus H, Leizorovicz A, Parent F, et al; Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med. 1998 Feb 12;338(7):409-15.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://www.nejm.org/doi/10.1056/NEJM199802123380701
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/9459643?tool=bestpractice.com
                                    </span>
                                    </span>
                                    Anticoagulation should be initiated if the contraindication resolves or if a risk/benefit analysis suggests this to be a reasonable course.
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;When retrievable filters are used, they should be removed as soon as it is safe to use anticoagulants.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                              </div>
                              <!--/.panel-body -->
                           </section>
                        </div>
                        <!--/.panel-body -->
                     </div>
                     <div class="panel">
                        <div class="panel-heading">
                           <h3>
                              <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" id="patientGroup-0-1">
                              <span>high risk or intermediate-high risk, contraindication to anticoagulation or thrombolysis</span>
                              <span class="hidden-sm-down">
                              <span class="msg">VIEW ALL</span>
                              <span class="material-icons" role="button"><span></span><span></span></span>
                              </span>
                              </a>
                           </h3>
                        </div>
                        <!--/.panel-heading -->
                        <div class="panel-body">
                           <section class="panel-group">
                              <div class="panel-header">
                                 <p class="panel-title"> 
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_1_0" aria-controls="panel_0_1_0" aria-expanded="false">
                                    <span class="titles-wrap col-md-12">
                                    <span class="title-02">
                                    <span class="title-03 col-md-1">
                                    1st line
                                    <span class="noShow">&nbsp;–&nbsp;</span>
                                    </span>
                                    <span class="title-04">
                                    <span class="material-icons"><span></span><span></span></span>
                                    <span class="txtwrap no-icon">respiratory support</span>
                                    </span>
                                    </span>
                                    </span>
                                    </a>
                                 </p>
                              </div>
                              <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_1_0" id="panel_0_1_0" aria-expanded="false">
                                 <!--  ADJUNCT/PLUS DISCLAIMER -->
                                 <!--/.treatment-wrap-->
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Supplemental high-concentration oxygen should be administered, targeting oxygen saturations of 94% to 98% (or 88% to 92% in patients at risk of hypercapnic respiratory failure).
                                    <span class="reference"> 
                                    <a href="#referencePop213" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[213]</a> 
                                    <span class="citationText" aria-hidden="true">O'Driscoll BR, Howard LS, Earis J, et al; British Thoracic Society Emergency Oxygen Guideline Group; BTS Emergency Oxygen Guideline Development Group. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax. 2017 Jun;72(Suppl 1):ii1-90.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://www.brit-thoracic.org.uk/document-library/clinical-information/oxygen/2017-emergency-oxygen-guideline/bts-guideline-for-oxygen-use-in-adults-in-healthcare-and-emergency-settings/
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/28507176?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Intubation and mechanical ventilation may be necessary for patients with severe hypoxaemia/respiratory failure. Mechanical ventilation can lead to hypotension, so BP should be monitored closely.
                                 </p>
                              </div>
                              <!--/.panel-body -->
                           </section>
                           <section class="panel-group">
                              <div class="panel-header">
                                 <p class="panel-title"> 
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_1_1" aria-controls="panel_0_1_1" aria-expanded="false">
                                    <span class="titles-wrap col-md-12">
                                    <span class="title-02">
                                    <span class="title-03 col-md-1">
                                    Plus
                                    <span class="noShow">&nbsp;–&nbsp;</span>
                                    </span>
                                    <span class="title-04">
                                    <span class="material-icons"><span></span><span></span></span>
                                    <span class="txtwrap no-icon">intravenous fluids</span>
                                    </span>
                                    </span>
                                    </span>
                                    </a>
                                 </p>
                              </div>
                              <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_1_1" id="panel_0_1_1" aria-expanded="false">
                                 <!--  ADJUNCT/PLUS DISCLAIMER -->
                                 <p class="w-75 smPopTxt">Treatment recommended for ALL patients in selected patient group</p>
                                 <!--/.treatment-wrap-->
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    If systolic BP is &lt;90 mmHg, intravenous fluids should be given. Acute right ventricular failure with resulting low systemic output is the leading cause of death in patients with PE.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Studies indicate that aggressive volume expansion is of no benefit, and may even worsen right ventricular function by causing mechanical overstretch, or by reflex mechanisms that depress contractility. However, modest fluid challenge (i.e., 500 mL) may be of benefit in patients with PE, a low cardiac index, and normal BP.
                                    <span class="reference"> 
                                    <a href="#referencePop168" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[168]</a> 
                                    <span class="citationText" aria-hidden="true">Mercat A, Diehl JL, Meyer G, et al. Hemodynamic effects of fluid loading in acute massive pulmonary embolism. Crit Care Med. 1999 Mar;27(3):540-4.</span> 
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/10199533?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                              </div>
                              <!--/.panel-body -->
                           </section>
                           <section class="panel-group">
                              <div class="panel-header">
                                 <p class="panel-title"> 
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_1_2" aria-controls="panel_0_1_2" aria-expanded="false">
                                    <span class="titles-wrap col-md-12">
                                    <span class="title-02">
                                    <span class="title-03 col-md-1">
                                    Plus
                                    <span class="noShow">&nbsp;–&nbsp;</span>
                                    </span>
                                    <span class="title-04">
                                    <span class="material-icons"><span></span><span></span></span>
                                    <span class="txtwrap no-icon">vasoactive agents</span>
                                    </span>
                                    </span>
                                    </span>
                                    </a>
                                 </p>
                              </div>
                              <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_1_2" id="panel_0_1_2" aria-expanded="false">
                                 <!--  ADJUNCT/PLUS DISCLAIMER -->
                                 <p class="w-75 smPopTxt">Treatment recommended for ALL patients in selected patient group</p>
                                 <div class="treatment-wrap">
                                    <!-- display regimens -->
                                    <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                    <h4>Primary options</h4>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_46d9672e-3313-452d-9bfd-a4ddf90b32f3_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">noradrenaline (norepinephrine)</a><span>: </span><span>0.5 to 1 microgram/minute intravenously initially, adjust according to response, usual dose range 2-12 micrograms/minute, maximum 30 micrograms/minute</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                    <p class="small-or">OR</p>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_a37dcf97-a50b-4776-ad01-6fd4a31bb295_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dobutamine</a><span>: </span><span>0.5 to 1 microgram/kg/minute intravenously initially, adjust according to response, usual dose range 2-20 micrograms/kg/minute, maximum 40 micrograms/kg/minute</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                    <p class="small-or">OR</p>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_b3fb3286-271c-47f6-ae52-1bd3958b1e9b_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">adrenaline (epinephrine)</a><span>: </span><span>1 microgram/minute intravenously initially, adjust according to response, usual dose range 2-10 micrograms/minute</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                 </div>
                                 <!--/.treatment-wrap-->
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    If systolic BP is &lt;90 mmHg, vasopressors may be given in parallel with (or while waiting for) pharmacological, surgical, or interventional re-perfusion treatment.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Noradrenaline (norepinephrine) may improve right ventricular function and right ventricular coronary perfusion.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;Its use should probably be limited to hypotensive patients.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Dobutamine enhances contractility with an increase in stroke volume and cardiac output. However, its systemic vasodilatory effect can lead to hypotension.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Adrenaline (epinephrine) combines the beneficial properties of noradrenaline (norepinephrine) (vasoconstriction with increased right ventricular perfusion, positive inotropy) and dobutamine (positive inotropy), but without the vasodilatory effects associated with the latter.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop214" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[214]</a> 
                                    <span class="citationText" aria-hidden="true">Layish DT, Tapson VF. Pharmacologic hemodynamic support in massive pulmonary embolism. Chest. 1997 Jan;111(1):218-24.</span> 
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/8996020?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                              </div>
                              <!--/.panel-body -->
                           </section>
                           <section class="panel-group">
                              <div class="panel-header">
                                 <p class="panel-title"> 
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_1_3" aria-controls="panel_0_1_3" aria-expanded="false">
                                    <span class="titles-wrap col-md-12">
                                    <span class="title-02">
                                    <span class="title-03 col-md-1">
                                    Plus
                                    <span class="noShow">&nbsp;–&nbsp;</span>
                                    </span>
                                    <span class="title-04">
                                    <span class="material-icons"><span></span><span></span></span>
                                    <span class="txtwrap no-icon">embolectomy and/or venous filter</span>
                                    </span>
                                    </span>
                                    </span>
                                    </a>
                                 </p>
                              </div>
                              <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_1_3" id="panel_0_1_3" aria-expanded="false">
                                 <!--  ADJUNCT/PLUS DISCLAIMER -->
                                 <p class="w-75 smPopTxt">Treatment recommended for ALL patients in selected patient group</p>
                                 <!--/.treatment-wrap-->
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Surgical pulmonary embolectomy has lower attendant bleeding risk than systemic therapy and may, therefore, be considered in high-risk patients unable to receive thrombolytic therapy because of bleeding risk.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop179" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[179]</a> 
                                    <span class="citationText" aria-hidden="true">Dolovich LR, Ginsberg JS, Douketis JD, et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med. 2000 Jan 24;160(2):181-8.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/485206
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/10647756?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop184" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[184]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Barco S. Systemic thrombolytic therapy for acute pulmonary embolism: who is a candidate? Semin Respir Crit Care Med. 2017 Feb;38(1):56-65.</span> 
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/28208199?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;Some centres insert inferior vena cava (IVC) filters intraoperatively or immediately postoperatively in patients who undergo surgical pulmonary embolectomy.
                                    <span class="reference"> 
                                    <a href="#referencePop185" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[185]</a> 
                                    <span class="citationText" aria-hidden="true">Leacche M, Unic D, Goldhaber SZ, et al. Modern surgical treatment of massive pulmonary embolism: Results in 47 consecutive patients after rapid diagnosis and aggressive surgical approach. J Thorac Cardiovasc Surg. 2005 May;129(5):1018-23.</span> 
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/15867775?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop218" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[218]</a> 
                                    <span class="citationText" aria-hidden="true">Aklog L, Williams CS, Byrne JG, et al. Acute pulmonary embolectomy: a contemporary approach. Circulation. 2002 Mar 26;105(12):1416-9.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://circ.ahajournals.org/content/105/12/1416.long
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/11914247?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop219" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[219]</a> 
                                    <span class="citationText" aria-hidden="true">Greelish JP, Leacche M, Solenkova NS, et al. Improved midterm outcomes for type A (central) pulmonary emboli treated surgically. J Thorac Cardiovasc Surg. 2011 Dec;142(6):1423-9.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://www.jtcvs.org/article/S0022-5223(11)00280-7/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/21481423?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Absolute contraindications to thrombolysis include: haemorrhagic stroke or stroke of unknown origin at any time; ischaemic stroke in the preceding 6 months; central nervous system damage or neoplasms; recent major trauma/surgery/head injury (in the preceding 3 weeks); gastrointestinal bleeding within the last month; known bleeding risk.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop177" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[177]</a> 
                                    <span class="citationText" aria-hidden="true">Van de Werf F, Ardissino D, Betriu A, et al; task force on the management of acute myocardial infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2003 Jan;24(1):28-66.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/24/1/28/562262
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/12559937?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    An IVC filter can be placed in patients with acute PE and an absolute contraindication to anticoagulant therapy.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop184" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[184]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Barco S. Systemic thrombolytic therapy for acute pulmonary embolism: who is a candidate? Semin Respir Crit Care Med. 2017 Feb;38(1):56-65.</span> 
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/28208199?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Observational studies suggest that insertion of a venous filter might reduce PE-related mortality rates in the acute phase but with an associated increase in the risk of filter-related venous thromboembolism.
                                    <span class="reference"> 
                                    <a href="#referencePop190" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[190]</a> 
                                    <span class="citationText" aria-hidden="true">Stein PD, Matta F, Keyes DC, et al. Impact of vena cava filters on in-hospital case fatality rate from pulmonary embolism. Am J Med. 2012 May;125(5):478-84.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://www.amjmed.com/article/S0002-9343(11)00481-5/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/22310013?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop191" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[191]</a> 
                                    <span class="citationText" aria-hidden="true">Muriel A, Jiménez D, Aujesky D, et al. Survival effects of inferior vena cava filter in patients with acute symptomatic venous thromboembolism and a significant bleeding risk. J Am Coll Cardiol. 2014 Apr 29;63(16):1675-83.</span> 
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/24576432?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Complications associated with permanent IVC filters are common, although they are rarely fatal.
                                    <span class="reference"> 
                                    <a href="#referencePop191" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[191]</a> 
                                    <span class="citationText" aria-hidden="true">Muriel A, Jiménez D, Aujesky D, et al. Survival effects of inferior vena cava filter in patients with acute symptomatic venous thromboembolism and a significant bleeding risk. J Am Coll Cardiol. 2014 Apr 29;63(16):1675-83.</span> 
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/24576432?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;Overall, early complications (including insertion-site thrombosis) occur in approximately 10% of patients. Late complications are more frequent and include recurrent DVT (approximately 20% of patients) and post-thrombotic syndrome (up to 40% of patients).
                                    <span class="reference"> 
                                    <a href="#referencePop192" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[192]</a> 
                                    <span class="citationText" aria-hidden="true">Rajasekhar A, Streiff MB. Vena cava filters for management of venous thromboembolism: a clinical review. Blood Rev. 2013 Sep;27(5):225-41.</span> 
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/23932118?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop193" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[193]</a> 
                                    <span class="citationText" aria-hidden="true">PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prévention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation. 2005 Jul 19;112(3):416-22.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://circ.ahajournals.org/content/112/3/416.long
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/16009794?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;Occlusion of the IVC affects approximately 22% of patients at 5 years and 33% at 9 years, regardless of the use and duration of anticoagulation.
                                    <span class="reference"> 
                                    <a href="#referencePop193" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[193]</a> 
                                    <span class="citationText" aria-hidden="true">PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prévention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation. 2005 Jul 19;112(3):416-22.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://circ.ahajournals.org/content/112/3/416.long
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/16009794?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Post-filter anticoagulation should be considered on a case-by-case basis according to relative and absolute contraindications.
                                    <span class="reference"> 
                                    <a href="#referencePop194" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[194]</a> 
                                    <span class="citationText" aria-hidden="true">Decousus H, Leizorovicz A, Parent F, et al; Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med. 1998 Feb 12;338(7):409-15.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://www.nejm.org/doi/10.1056/NEJM199802123380701
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/9459643?tool=bestpractice.com
                                    </span>
                                    </span>
                                    Anticoagulation should be initiated if the contraindication resolves or if a risk/benefit analysis suggests this to be a reasonable course.
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;When retrievable filters are used, they should be removed as soon as it is safe to use anticoagulants.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                              </div>
                              <!--/.panel-body -->
                           </section>
                        </div>
                        <!--/.panel-body -->
                     </div>
                     <div class="panel">
                        <div class="panel-heading">
                           <h3>
                              <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" id="patientGroup-0-2">
                              <span>intermediate-high risk PESI/sPESI score, no contraindication to anticoagulation or thrombolysis</span>
                              <span class="hidden-sm-down">
                              <span class="msg">VIEW ALL</span>
                              <span class="material-icons" role="button"><span></span><span></span></span>
                              </span>
                              </a>
                           </h3>
                        </div>
                        <!--/.panel-heading -->
                        <div class="panel-body">
                           <section class="panel-group">
                              <div class="panel-header">
                                 <p class="panel-title"> 
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_2_0" aria-controls="panel_0_2_0" aria-expanded="false">
                                    <span class="titles-wrap col-md-12">
                                    <span class="title-02">
                                    <span class="title-03 col-md-1">
                                    1st line
                                    <span class="noShow">&nbsp;–&nbsp;</span>
                                    </span>
                                    <span class="title-04">
                                    <span class="material-icons"><span></span><span></span></span>
                                    <span class="txtwrap no-icon">respiratory support</span>
                                    </span>
                                    </span>
                                    </span>
                                    </a>
                                 </p>
                              </div>
                              <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_2_0" id="panel_0_2_0" aria-expanded="false">
                                 <!--  ADJUNCT/PLUS DISCLAIMER -->
                                 <!--/.treatment-wrap-->
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Supplemental high-concentration oxygen should be administered, targeting oxygen saturations of 94% to 98% (or 88% to 92% in patients at risk of hypercapnic respiratory failure).
                                    <span class="reference"> 
                                    <a href="#referencePop213" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[213]</a> 
                                    <span class="citationText" aria-hidden="true">O'Driscoll BR, Howard LS, Earis J, et al; British Thoracic Society Emergency Oxygen Guideline Group; BTS Emergency Oxygen Guideline Development Group. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax. 2017 Jun;72(Suppl 1):ii1-90.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://www.brit-thoracic.org.uk/document-library/clinical-information/oxygen/2017-emergency-oxygen-guideline/bts-guideline-for-oxygen-use-in-adults-in-healthcare-and-emergency-settings/
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/28507176?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Intubation and mechanical ventilation may be necessary for patients with severe hypoxaemia/respiratory failure. Mechanical ventilation can lead to hypotension, so BP should be monitored closely.
                                 </p>
                              </div>
                              <!--/.panel-body -->
                           </section>
                           <section class="panel-group">
                              <div class="panel-header">
                                 <p class="panel-title"> 
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_2_1" aria-controls="panel_0_2_1" aria-expanded="false">
                                    <span class="titles-wrap col-md-12">
                                    <span class="title-02">
                                    <span class="title-03 col-md-1">
                                    Plus
                                    <span class="noShow">&nbsp;–&nbsp;</span>
                                    </span>
                                    <span class="title-04">
                                    <span class="material-icons"><span></span><span></span></span>
                                    <span class="txtwrap no-icon">anticoagulation</span>
                                    </span>
                                    </span>
                                    </span>
                                    </a>
                                 </p>
                              </div>
                              <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_2_1" id="panel_0_2_1" aria-expanded="false">
                                 <!--  ADJUNCT/PLUS DISCLAIMER -->
                                 <p class="w-75 smPopTxt">Treatment recommended for ALL patients in selected patient group</p>
                                 <div class="treatment-wrap">
                                    <!-- display regimens -->
                                    <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                    <h4>Primary options</h4>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_0f8c4ada-cd84-4c04-8860-01a81e07c1f9_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">rivaroxaban</a><span>: </span><span>15 mg orally twice daily initially for 3 weeks, followed by 20 mg once daily</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                    <p class="small-or">OR</p>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_aff9d94e-1579-4f56-acb7-73775d12d818_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">apixaban</a><span>: </span><span>10 mg orally twice daily for 7 days, followed by 5 mg twice daily</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                    <p class="small-or">OR</p>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_6402d40a-aa86-4def-a6af-9d56b0e8ef3e_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dabigatran</a><span>: </span><span>150 mg orally twice daily, starting 5-10 days after treatment with a parenteral anticoagulant</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                    <p class="small-or">OR</p>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_4b33f194-29da-4239-aae9-c1746e2bda94_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">edoxaban</a><span>: </span><span>body weight ≤60 kg: 30 mg orally once daily, starting 5-10 days after treatment with a parenteral anticoagulant; body weight &gt;60 kg: 60 mg orally once daily, starting 5-10 days after treatment with a parenteral anticoagulant</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                    <p class="small-or">OR</p>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">heparin</a><span>: </span><span>80 units/kg intravenous bolus initially, followed by 18 units/kg/hour intravenous infusion, adjust dose according to aPTT; 333 units/kg subcutaneously initially, followed by 250 units/kg every 12 hours</span>
                                       </p>
                                       <p class="small-or">and</p>
                                       <p>
                                          <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">warfarin</a><span>: </span><span>5 mg orally once daily initially, adjust according to INR (goal INR is 2 to 3)</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                 </div>
                                 <div class="treatment-wrap">
                                    <!-- display regimens -->
                                    <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                    <h4>Secondary options</h4>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_3984222a-c42a-4f8a-bff1-f99645ade85d_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">enoxaparin</a><span>: </span><span>1 mg/kg subcutaneously twice daily; or 1.5 mg/kg subcutaneously once daily</span>
                                       </p>
                                       <p class="small-or">and</p>
                                       <p>
                                          <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">warfarin</a><span>: </span><span>5 mg orally once daily initially, adjust according to INR (goal INR is 2 to 3)</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                    <p class="small-or">OR</p>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_d4ccd444-8501-447d-848f-bc97c03774ba_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dalteparin</a><span>: </span><span>200 units/kg subcutaneously once daily, maximum 18,000 units/dose; or 100 units/kg subcutaneously twice daily</span>
                                       </p>
                                       <p class="small-or">and</p>
                                       <p>
                                          <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">warfarin</a><span>: </span><span>5 mg orally once daily initially, adjust according to INR (goal INR is 2 to 3)</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                    <p class="small-or">OR</p>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_a4adb6a6-1e28-4057-9789-361aa3c914b8_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">fondaparinux</a><span>: </span><span>body weight &lt;50 kg: 5 mg subcutaneously once daily; body weight 50-100 kg: 7.5 mg subcutaneously once daily; body weight &gt;100 kg: 10 mg subcutaneously once daily</span>
                                       </p>
                                       <p class="small-or">and</p>
                                       <p>
                                          <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">warfarin</a><span>: </span><span>5 mg orally once daily initially, adjust according to INR (goal INR is 2 to 3)</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                 </div>
                                 <!--/.treatment-wrap-->
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Patients who present with suspected PE should receive an anticoagulant in the acute phase (the initial 10-day period following PE diagnosis), unless contraindicated.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;If PE is subsequently excluded, anticoagulation can be discontinued. In patients with confirmed PE, anticoagulation should continue for at least 3 months.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop101" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[101]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Barco S, Lankeit M, et al. Management of pulmonary embolism: an update. J Am Coll Cardiol. 2016 Mar 1;67(8):976-90.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://www.onlinejacc.org/content/67/8/976
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26916489?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;Acute-phase parenteral anticoagulation (unfractionated heparin [UFH], low molecular weight heparin [LMWH], or fondaparinux) should overlap with the initiation of a vitamin K antagonist (VKA).
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    The direct-acting oral anticoagulants rivaroxaban and apixaban may be prescribed without the need for pre-treatment with a parenteral anticoagulant. However, both dabigatran and edoxaban require lead-in therapy with a parenteral anticoagulant for 5 to 10 days. One meta-analysis found that direct-acting oral anticoagulants have similar efficacy to a heparin/VKA regimen, but with reduced risk of major bleeding (relative risk 0.61, 95% CI 0.21 to 0.68).
                                    <span class="reference"> 
                                    <a href="#referencePop101" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[101]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Barco S, Lankeit M, et al. Management of pulmonary embolism: an update. J Am Coll Cardiol. 2016 Mar 1;67(8):976-90.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://www.onlinejacc.org/content/67/8/976
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26916489?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop215" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[215]</a> 
                                    <span class="citationText" aria-hidden="true">van Es N, Coppens M, Schulman S, et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014 Sep 18;124(12):1968-75.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://www.bloodjournal.org/content/124/12/1968.long
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/24963045?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;Furthermore, direct-acting oral anticoagulants do not require monitoring, have a rapid onset of action, and are short-acting. They do not interact with food, but they can interact with other pharmacotherapeutic agents. Dabigatran can be reversed with idarucizumab. Andexanet alfa is approved by the FDA for the reversal of apixaban- and rivaroxaban-mediated anticoagulation in patients with life-threatening or uncontrolled bleeding. At present there is no approved reversal agent for edoxaban.
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Parenteral anticoagulation with UFH for a minimum of 5 days is the preferred acute-phase treatment for patients with high-risk PE (in whom primary re-perfusion [i.e., systemic thrombolytic therapy or embolectomy] is considered).
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;Parenteral UFH can be stopped once a therapeutic INR of 2.0 to 3.0 has been established.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop101" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[101]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Barco S, Lankeit M, et al. Management of pulmonary embolism: an update. J Am Coll Cardiol. 2016 Mar 1;67(8):976-90.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://www.onlinejacc.org/content/67/8/976
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26916489?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;UFH has a short half-life, is easy to monitor, and is readily reversed by protamine.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Parenteral anticoagulation with low molecular weight heparin (LMWH) or fondaparinux (with overlapping treatment with a vitamin K antagonist [VKA], ideally beginning on the same day as parenteral therapy) may be used during the acute phase.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop101" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[101]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Barco S, Lankeit M, et al. Management of pulmonary embolism: an update. J Am Coll Cardiol. 2016 Mar 1;67(8):976-90.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://www.onlinejacc.org/content/67/8/976
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26916489?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;Parenteral anticoagulant administration can be stopped once a therapeutic INR of 2.0 to 3.0 has been established.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop101" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[101]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Barco S, Lankeit M, et al. Management of pulmonary embolism: an update. J Am Coll Cardiol. 2016 Mar 1;67(8):976-90.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://www.onlinejacc.org/content/67/8/976
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26916489?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    European guidelines recommend UFH for obese patients, and for patients with severe renal impairment (creatinine clearance &lt;30 mL/minute).
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;The American College of Chest Physicians recommends a VKA for patients with severe renal impairment.
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    LMWH is the preferred agent for initial anticoagulation in patients with active cancer, or hepatic impairment and coagulopathy.
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" data-trigger="click focus" data-toggle="popover" class="cochranePop" data-original-title="" title="">
                                    [ <img src="../images/cca-cochrane-logo-inline.png" alt="Cochrane Clinical Answers logo"> ] 
                                    </a>
                                    <span class="ccaTitle" aria-hidden="true">How do low‐molecular‐weight heparin (LMWH), vitamin K agonists (VKAs), and direct oral anticoagulants (DOACs) compare for treatment of venous thromboembolism (VTE) in people with cancer?</span>
                                    <span class="ccaUrl" aria-hidden="true">/cca.html?targetUrl=https://cochranelibrary.com/cca/doi/10.1002/cca.2255/full</span>
                                    <span class="ccaHrefText" aria-hidden="true">Show me the answer</span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Health professionals should refer to the label and/or local formularies before prescribing a direct-acting oral anticoagulant for a patient with renal or hepatic impairment.
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Fondaparinux carries a low risk of inducing heparin-induced thrombocytopenia (HIT) and appears to be effective for patients with suspected or confirmed HIT.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop216" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[216]</a> 
                                    <span class="citationText" aria-hidden="true">Kang M, Alahmadi M, Sawh S, et al. Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study. Blood. 2015 Feb 5;125(6):924-9.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://www.bloodjournal.org/content/125/6/924.long
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25515959?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;It is contraindicated in patients with severe renal impairment.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    LMWH is recommended for women who are pregnant (weight-adjusted dose, consult specialist for guidance) or who may be pregnant.
                                    <span class="reference"> 
                                    <a href="#referencePop36" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[36]</a> 
                                    <span class="citationText" aria-hidden="true">Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(2 Suppl):e691S-736S.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(12)60136-6/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/22315276?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;It does not cross the placenta, and routine monitoring is not generally required.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop212" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[212]</a> 
                                    <span class="citationText" aria-hidden="true">Royal College of Obstetricians and Gynaecologists. Reducing the risk of venous thromboembolism during pregnancy and the puerperium. Green-top guideline No. 37a. Apr 2015 [internet publication].</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://www.rcog.org.uk/globalassets/documents/guidelines/gtg-37a.pdf
                                    </span>
                                    </span>
                                    &nbsp;Other anticoagulants, including VKAs, may cross the placenta.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                              </div>
                              <!--/.panel-body -->
                           </section>
                           <section class="panel-group">
                              <div class="panel-header">
                                 <p class="panel-title"> 
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_2_2" aria-controls="panel_0_2_2" aria-expanded="false">
                                    <span class="titles-wrap col-md-12">
                                    <span class="title-02">
                                    <span class="title-03 col-md-1">
                                    Adjunct
                                    <span class="noShow">&nbsp;–&nbsp;</span>
                                    </span>
                                    <span class="title-04">
                                    <span class="material-icons"><span></span><span></span></span>
                                    <span class="txtwrap no-icon">intravenous fluids</span>
                                    </span>
                                    </span>
                                    </span>
                                    </a>
                                 </p>
                              </div>
                              <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_2_2" id="panel_0_2_2" aria-expanded="false">
                                 <!--  ADJUNCT/PLUS DISCLAIMER -->
                                 <p class="w-75 smPopTxt">Treatment recommended for SOME patients in selected patient group</p>
                                 <!--/.treatment-wrap-->
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    If systolic BP falls below 90 mmHg, intravenous fluids should be given. Acute right ventricular failure with resulting low systemic output is the leading cause of death in patients with PE.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Studies indicate that aggressive volume expansion is of no benefit, and may even worsen right ventricular function by causing mechanical overstretch, or by reflex mechanisms that depress contractility. However, modest fluid challenge (i.e., 500 mL) may be of benefit in patients with PE, a low cardiac index, and normal BP.
                                    <span class="reference"> 
                                    <a href="#referencePop168" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[168]</a> 
                                    <span class="citationText" aria-hidden="true">Mercat A, Diehl JL, Meyer G, et al. Hemodynamic effects of fluid loading in acute massive pulmonary embolism. Crit Care Med. 1999 Mar;27(3):540-4.</span> 
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/10199533?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                              </div>
                              <!--/.panel-body -->
                           </section>
                           <section class="panel-group">
                              <div class="panel-header">
                                 <p class="panel-title"> 
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_2_3" aria-controls="panel_0_2_3" aria-expanded="false">
                                    <span class="titles-wrap col-md-12">
                                    <span class="title-02">
                                    <span class="title-03 col-md-1">
                                    Adjunct
                                    <span class="noShow">&nbsp;–&nbsp;</span>
                                    </span>
                                    <span class="title-04">
                                    <span class="material-icons"><span></span><span></span></span>
                                    <span class="txtwrap no-icon">thrombolysis or embolectomy or catheter-directed therapy</span>
                                    </span>
                                    </span>
                                    </span>
                                    </a>
                                 </p>
                              </div>
                              <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_2_3" id="panel_0_2_3" aria-expanded="false">
                                 <!--  ADJUNCT/PLUS DISCLAIMER -->
                                 <p class="w-75 smPopTxt">Treatment recommended for SOME patients in selected patient group</p>
                                 <div class="treatment-wrap">
                                    <!-- display regimens -->
                                    <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                    <h4>Primary options</h4>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_89dc308c-7daa-4c1f-a0c4-829a581f1936_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">alteplase</a><span>: </span><span>100 mg intravenously given over 2 hours</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                    <p class="small-or">OR</p>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_88583afa-6bbd-4755-a21e-c63ab12370f0_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">reteplase</a><span>: </span><span>10 units intravenously initially, followed by second dose of 10 units 30 minutes later</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                 </div>
                                 <!--/.treatment-wrap-->
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Those with PESI risk stratification ≥III or sPESI ≥1 with right ventricular dysfunction and a positive cardiac troponin I or T test belong to an intermediate high-risk group.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;Rescue thrombolysis may be indicated in intermediate high-risk patients, and in patients with other clinical features of cardiopulmonary impairment (e.g., elevated heart rate, respiratory rate, jugular venous pressure) who have started anticoagulant therapy, and: are deteriorating, but have not yet developed hypotension; are exhibiting signs of haemodynamic decompensation (e.g., systolic BP &lt;90 mmHg for at least 15 minutes, or drop of systolic BP by at least 40 mmHg for at least 15 minutes with signs of end organ hypoperfusion).
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop184" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[184]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Barco S. Systemic thrombolytic therapy for acute pulmonary embolism: who is a candidate? Semin Respir Crit Care Med. 2017 Feb;38(1):56-65.</span> 
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/28208199?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;Consideration of bleeding risk will inform choice of thrombolytic therapy. 
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Absolute contraindications to thrombolysis include: haemorrhagic stroke or stroke of unknown origin at any time; ischaemic stroke in the preceding 6 months; central nervous system damage or neoplasms; recent major trauma/surgery/head injury (in the preceding 3 weeks); gastrointestinal bleeding within the last month; known bleeding risk.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop177" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[177]</a> 
                                    <span class="citationText" aria-hidden="true">Van de Werf F, Ardissino D, Betriu A, et al; task force on the management of acute myocardial infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2003 Jan;24(1):28-66.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/24/1/28/562262
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/12559937?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Surgical pulmonary embolectomy and catheter-directed therapy have lower attendant bleeding risk than systemic therapy and may, therefore, be considered in high-risk patients unable to receive thrombolytic therapy because of bleeding risk, or when there is insufficient time for effective systemic thrombolytic therapy, or when such therapy has failed.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop179" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[179]</a> 
                                    <span class="citationText" aria-hidden="true">Dolovich LR, Ginsberg JS, Douketis JD, et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med. 2000 Jan 24;160(2):181-8.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/485206
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/10647756?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop184" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[184]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Barco S. Systemic thrombolytic therapy for acute pulmonary embolism: who is a candidate? Semin Respir Crit Care Med. 2017 Feb;38(1):56-65.</span> 
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/28208199?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Surgical pulmonary embolectomy is recommended for patients in whom systemic thrombolytic therapy has failed or is absolutely contraindicated.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Catheter-directed therapy, which typically involves a combination of mechanical and pharmacotherapeutic thrombus fragmentation, may be considered for patients in whom full-dose systemic thrombolytic therapy has failed.
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;Catheter-directed therapy uses a lower dose of thrombolytic drug (approximately one third of full-dose systemic thrombolytic therapy) and is believed to reduce the risks of bleeding at remote sites (for example, intracranially or gastrointestinally).
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                              </div>
                              <!--/.panel-body -->
                           </section>
                        </div>
                        <!--/.panel-body -->
                     </div>
                     <div class="panel">
                        <div class="panel-heading">
                           <h3>
                              <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" id="patientGroup-0-3">
                              <span>intermediate-low risk or low risk PESI/sPESI score, no contraindication to anticoagulation</span>
                              <span class="hidden-sm-down">
                              <span class="msg">VIEW ALL</span>
                              <span class="material-icons" role="button"><span></span><span></span></span>
                              </span>
                              </a>
                           </h3>
                        </div>
                        <!--/.panel-heading -->
                        <div class="panel-body">
                           <section class="panel-group">
                              <div class="panel-header">
                                 <p class="panel-title"> 
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_3_0" aria-controls="panel_0_3_0" aria-expanded="false">
                                    <span class="titles-wrap col-md-12">
                                    <span class="title-02">
                                    <span class="title-03 col-md-1">
                                    1st line
                                    <span class="noShow">&nbsp;–&nbsp;</span>
                                    </span>
                                    <span class="title-04">
                                    <span class="material-icons"><span></span><span></span></span>
                                    <span class="txtwrap no-icon">oxygen</span>
                                    </span>
                                    </span>
                                    </span>
                                    </a>
                                 </p>
                              </div>
                              <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_3_0" id="panel_0_3_0" aria-expanded="false">
                                 <!--  ADJUNCT/PLUS DISCLAIMER -->
                                 <!--/.treatment-wrap-->
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Supplemental high-concentration oxygen may be required. Target oxygen saturations of 94% to 98% (or 88% to 92% in patients at risk of hypercapnic respiratory failure).
                                    <span class="reference"> 
                                    <a href="#referencePop213" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[213]</a> 
                                    <span class="citationText" aria-hidden="true">O'Driscoll BR, Howard LS, Earis J, et al; British Thoracic Society Emergency Oxygen Guideline Group; BTS Emergency Oxygen Guideline Development Group. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax. 2017 Jun;72(Suppl 1):ii1-90.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://www.brit-thoracic.org.uk/document-library/clinical-information/oxygen/2017-emergency-oxygen-guideline/bts-guideline-for-oxygen-use-in-adults-in-healthcare-and-emergency-settings/
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/28507176?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                              </div>
                              <!--/.panel-body -->
                           </section>
                           <section class="panel-group">
                              <div class="panel-header">
                                 <p class="panel-title"> 
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_3_1" aria-controls="panel_0_3_1" aria-expanded="false">
                                    <span class="titles-wrap col-md-12">
                                    <span class="title-02">
                                    <span class="title-03 col-md-1">
                                    Plus
                                    <span class="noShow">&nbsp;–&nbsp;</span>
                                    </span>
                                    <span class="title-04">
                                    <span class="material-icons"><span></span><span></span></span>
                                    <span class="txtwrap no-icon">anticoagulation</span>
                                    </span>
                                    </span>
                                    </span>
                                    </a>
                                 </p>
                              </div>
                              <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_3_1" id="panel_0_3_1" aria-expanded="false">
                                 <!--  ADJUNCT/PLUS DISCLAIMER -->
                                 <p class="w-75 smPopTxt">Treatment recommended for ALL patients in selected patient group</p>
                                 <div class="treatment-wrap">
                                    <!-- display regimens -->
                                    <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                    <h4>Primary options</h4>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_0f8c4ada-cd84-4c04-8860-01a81e07c1f9_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">rivaroxaban</a><span>: </span><span>15 mg orally twice daily initially for 3 weeks, followed by 20 mg once daily</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                    <p class="small-or">OR</p>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_aff9d94e-1579-4f56-acb7-73775d12d818_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">apixaban</a><span>: </span><span>10 mg orally twice daily for 7 days, followed by 5 mg twice daily</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                    <p class="small-or">OR</p>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_6402d40a-aa86-4def-a6af-9d56b0e8ef3e_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dabigatran</a><span>: </span><span>150 mg orally twice daily, starting 5-10 days after treatment with a parenteral anticoagulant</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                    <p class="small-or">OR</p>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_4b33f194-29da-4239-aae9-c1746e2bda94_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">edoxaban</a><span>: </span><span>body weight ≤60 kg: 30 mg orally once daily, starting 5-10 days after treatment with a parenteral anticoagulant; body weight &gt;60 kg: 60 mg orally once daily, starting 5-10 days after treatment with a parenteral anticoagulant</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                 </div>
                                 <div class="treatment-wrap">
                                    <!-- display regimens -->
                                    <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                    <h4>Secondary options</h4>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_3984222a-c42a-4f8a-bff1-f99645ade85d_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">enoxaparin</a><span>: </span><span>1 mg/kg subcutaneously twice daily; or 1.5 mg/kg subcutaneously once daily</span>
                                       </p>
                                       <p class="small-or">and</p>
                                       <p>
                                          <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">warfarin</a><span>: </span><span>5 mg orally once daily initially, adjust according to INR (goal INR is 2 to 3)</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                    <p class="small-or">OR</p>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_d4ccd444-8501-447d-848f-bc97c03774ba_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dalteparin</a><span>: </span><span>200 units/kg subcutaneously once daily, maximum 18,000 units/dose; or 100 units/kg subcutaneously twice daily</span>
                                       </p>
                                       <p class="small-or">and</p>
                                       <p>
                                          <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">warfarin</a><span>: </span><span>5 mg orally once daily initially, adjust according to INR (goal INR is 2 to 3)</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                    <p class="small-or">OR</p>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_a4adb6a6-1e28-4057-9789-361aa3c914b8_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">fondaparinux</a><span>: </span><span>body weight &lt;50 kg: 5 mg subcutaneously once daily; body weight 50-100 kg: 7.5 mg subcutaneously once daily; body weight &gt;100 kg: 10 mg subcutaneously once daily</span>
                                       </p>
                                       <p class="small-or">and</p>
                                       <p>
                                          <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">warfarin</a><span>: </span><span>5 mg orally once daily initially, adjust according to INR (goal INR is 2 to 3)</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                    <p class="small-or">OR</p>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_4866ce04-4d68-4b50-83f4-66283ea52c07_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">heparin</a><span>: </span><span>80 units/kg intravenous bolus initially, followed by 18 units/kg/hour intravenous infusion, adjust dose according to aPTT; 333 units/kg subcutaneously initially, followed by 250 units/kg every 12 hours</span>
                                       </p>
                                       <p class="small-or">and</p>
                                       <p>
                                          <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">warfarin</a><span>: </span><span>5 mg orally once daily initially, adjust according to INR (goal INR is 2 to 3)</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                 </div>
                                 <!--/.treatment-wrap-->
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Patients who present with suspected PE should receive an anticoagulant in the acute phase (the initial 10-day period following PE diagnosis), unless contraindicated.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;If PE is subsequently excluded, anticoagulation can be discontinued. In patients with confirmed PE, anticoagulation should continue for at least 3 months.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop101" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[101]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Barco S, Lankeit M, et al. Management of pulmonary embolism: an update. J Am Coll Cardiol. 2016 Mar 1;67(8):976-90.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://www.onlinejacc.org/content/67/8/976
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26916489?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;Acute-phase parenteral anticoagulation (unfractionated heparin [UFH], low molecular weight heparin [LMWH], or fondaparinux) should overlap with the initiation of a vitamin K antagonist (VKA). Parenteral anticoagulation can be stopped once a therapeutic INR of 2.0 to 3.0 has been established.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop101" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[101]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Barco S, Lankeit M, et al. Management of pulmonary embolism: an update. J Am Coll Cardiol. 2016 Mar 1;67(8):976-90.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://www.onlinejacc.org/content/67/8/976
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26916489?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    The direct-acting oral anticoagulants rivaroxaban and apixaban may be prescribed without the need for pre-treatment with a parenteral anticoagulant. However, both dabigatran and edoxaban require lead-in therapy with a parenteral anticoagulant for 5 to 10 days. One meta-analysis found that direct-acting oral anticoagulants have similar efficacy to a heparin/VKA regimen, but with reduced risk of major bleeding (relative risk 0.61, 95% CI 0.21 to 0.68).
                                    <span class="reference"> 
                                    <a href="#referencePop101" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[101]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Barco S, Lankeit M, et al. Management of pulmonary embolism: an update. J Am Coll Cardiol. 2016 Mar 1;67(8):976-90.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://www.onlinejacc.org/content/67/8/976
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26916489?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop215" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[215]</a> 
                                    <span class="citationText" aria-hidden="true">van Es N, Coppens M, Schulman S, et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014 Sep 18;124(12):1968-75.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://www.bloodjournal.org/content/124/12/1968.long
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/24963045?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;Furthermore, direct-acting oral anticoagulants do not require monitoring, have a rapid onset of action, and are short-acting. They do not interact with food, but they can interact with other pharmacotherapeutic agents. Dabigatran can be reversed with idarucizumab. Andexanet alfa is approved by the FDA for the reversal of apixaban- and rivaroxaban-mediated anticoagulation in patients with life-threatening or uncontrolled bleeding. At present there is no approved reversal agent for edoxaban.
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    European guidelines recommend UFH for obese patients, and for patients with severe renal impairment (creatinine clearance &lt;30 mL/minute).
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;The American College of Chest Physicians recommends a VKA for patients with severe renal impairment.
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    LMWH is the preferred agent for initial anticoagulation in patients with active cancer, or hepatic impairment and coagulopathy.
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" data-trigger="click focus" data-toggle="popover" class="cochranePop" data-original-title="" title="">
                                    [ <img src="../images/cca-cochrane-logo-inline.png" alt="Cochrane Clinical Answers logo"> ] 
                                    </a>
                                    <span class="ccaTitle" aria-hidden="true">How do low‐molecular‐weight heparin (LMWH), vitamin K agonists (VKAs), and direct oral anticoagulants (DOACs) compare for treatment of venous thromboembolism (VTE) in people with cancer?</span>
                                    <span class="ccaUrl" aria-hidden="true">/cca.html?targetUrl=https://cochranelibrary.com/cca/doi/10.1002/cca.2255/full</span>
                                    <span class="ccaHrefText" aria-hidden="true">Show me the answer</span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Health professionals should refer to the label and/or local formularies before prescribing a direct-acting oral anticoagulant for a patient with renal or hepatic impairment.
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Fondaparinux carries a low risk of inducing heparin-induced thrombocytopenia (HIT) and appears to be effective for patients with suspected or confirmed HIT.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop216" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[216]</a> 
                                    <span class="citationText" aria-hidden="true">Kang M, Alahmadi M, Sawh S, et al. Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study. Blood. 2015 Feb 5;125(6):924-9.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://www.bloodjournal.org/content/125/6/924.long
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25515959?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;It is contraindicated in patients with severe renal impairment.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    LMWH is recommended for women who are pregnant (weight-adjusted dose, consult specialist for guidance) or who may be pregnant.
                                    <span class="reference"> 
                                    <a href="#referencePop36" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[36]</a> 
                                    <span class="citationText" aria-hidden="true">Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(2 Suppl):e691S-736S.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(12)60136-6/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/22315276?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;It does not cross the placenta, and routine monitoring is not generally required.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop212" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[212]</a> 
                                    <span class="citationText" aria-hidden="true">Royal College of Obstetricians and Gynaecologists. Reducing the risk of venous thromboembolism during pregnancy and the puerperium. Green-top guideline No. 37a. Apr 2015 [internet publication].</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://www.rcog.org.uk/globalassets/documents/guidelines/gtg-37a.pdf
                                    </span>
                                    </span>
                                    &nbsp;Other anticoagulants, including VKAs, may cross the placenta.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Low-risk patients (PESI class I or class II), and potentially those with a sPESI score of 0, can be considered for early discharge and outpatient management.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;Social background and likely compliance with treatment should also inform the decision.
                                 </p>
                              </div>
                              <!--/.panel-body -->
                           </section>
                        </div>
                        <!--/.panel-body -->
                     </div>
                     <div class="panel">
                        <div class="panel-heading">
                           <h3>
                              <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" id="patientGroup-0-4">
                              <span>intermediate-low risk or low risk PESI/sPESI score, contraindication to anticoagulation</span>
                              <span class="hidden-sm-down">
                              <span class="msg">VIEW ALL</span>
                              <span class="material-icons" role="button"><span></span><span></span></span>
                              </span>
                              </a>
                           </h3>
                        </div>
                        <!--/.panel-heading -->
                        <div class="panel-body">
                           <section class="panel-group">
                              <div class="panel-header">
                                 <p class="panel-title"> 
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_4_0" aria-controls="panel_0_4_0" aria-expanded="false">
                                    <span class="titles-wrap col-md-12">
                                    <span class="title-02">
                                    <span class="title-03 col-md-1">
                                    1st line
                                    <span class="noShow">&nbsp;–&nbsp;</span>
                                    </span>
                                    <span class="title-04">
                                    <span class="material-icons"><span></span><span></span></span>
                                    <span class="txtwrap no-icon">oxygen</span>
                                    </span>
                                    </span>
                                    </span>
                                    </a>
                                 </p>
                              </div>
                              <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_4_0" id="panel_0_4_0" aria-expanded="false">
                                 <!--  ADJUNCT/PLUS DISCLAIMER -->
                                 <!--/.treatment-wrap-->
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Supplemental high-concentration oxygen may be required. Target oxygen saturations of 94% to 98% (or 88% to 92% in patients at risk of hypercapnic respiratory failure).
                                    <span class="reference"> 
                                    <a href="#referencePop213" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[213]</a> 
                                    <span class="citationText" aria-hidden="true">O'Driscoll BR, Howard LS, Earis J, et al; British Thoracic Society Emergency Oxygen Guideline Group; BTS Emergency Oxygen Guideline Development Group. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax. 2017 Jun;72(Suppl 1):ii1-90.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://www.brit-thoracic.org.uk/document-library/clinical-information/oxygen/2017-emergency-oxygen-guideline/bts-guideline-for-oxygen-use-in-adults-in-healthcare-and-emergency-settings/
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/28507176?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                              </div>
                              <!--/.panel-body -->
                           </section>
                           <section class="panel-group">
                              <div class="panel-header">
                                 <p class="panel-title"> 
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_0_4_1" aria-controls="panel_0_4_1" aria-expanded="false">
                                    <span class="titles-wrap col-md-12">
                                    <span class="title-02">
                                    <span class="title-03 col-md-1">
                                    Plus
                                    <span class="noShow">&nbsp;–&nbsp;</span>
                                    </span>
                                    <span class="title-04">
                                    <span class="material-icons"><span></span><span></span></span>
                                    <span class="txtwrap no-icon">venous filter</span>
                                    </span>
                                    </span>
                                    </span>
                                    </a>
                                 </p>
                              </div>
                              <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_0_4_1" id="panel_0_4_1" aria-expanded="false">
                                 <!--  ADJUNCT/PLUS DISCLAIMER -->
                                 <p class="w-75 smPopTxt">Treatment recommended for ALL patients in selected patient group</p>
                                 <!--/.treatment-wrap-->
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    An inferior vena cava (IVC) filter can be placed in patients with acute PE and an absolute contraindication to anticoagulant therapy.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop184" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[184]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Barco S. Systemic thrombolytic therapy for acute pulmonary embolism: who is a candidate? Semin Respir Crit Care Med. 2017 Feb;38(1):56-65.</span> 
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/28208199?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Observational studies suggest that insertion of a venous filter might reduce PE-related mortality rates in the acute phase but with an associated increase in the risk of filter-related venous thromboembolism.
                                    <span class="reference"> 
                                    <a href="#referencePop190" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[190]</a> 
                                    <span class="citationText" aria-hidden="true">Stein PD, Matta F, Keyes DC, et al. Impact of vena cava filters on in-hospital case fatality rate from pulmonary embolism. Am J Med. 2012 May;125(5):478-84.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://www.amjmed.com/article/S0002-9343(11)00481-5/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/22310013?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop191" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[191]</a> 
                                    <span class="citationText" aria-hidden="true">Muriel A, Jiménez D, Aujesky D, et al. Survival effects of inferior vena cava filter in patients with acute symptomatic venous thromboembolism and a significant bleeding risk. J Am Coll Cardiol. 2014 Apr 29;63(16):1675-83.</span> 
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/24576432?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Complications associated with permanent IVC filters are common, although they are rarely fatal.
                                    <span class="reference"> 
                                    <a href="#referencePop191" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[191]</a> 
                                    <span class="citationText" aria-hidden="true">Muriel A, Jiménez D, Aujesky D, et al. Survival effects of inferior vena cava filter in patients with acute symptomatic venous thromboembolism and a significant bleeding risk. J Am Coll Cardiol. 2014 Apr 29;63(16):1675-83.</span> 
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/24576432?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;Overall, early complications (including insertion-site thrombosis) occur in approximately 10% of patients. Late complications are more frequent and include recurrent DVT (approximately 20% of patients) and post-thrombotic syndrome (up to 40% of patients).
                                    <span class="reference"> 
                                    <a href="#referencePop192" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[192]</a> 
                                    <span class="citationText" aria-hidden="true">Rajasekhar A, Streiff MB. Vena cava filters for management of venous thromboembolism: a clinical review. Blood Rev. 2013 Sep;27(5):225-41.</span> 
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/23932118?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop193" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[193]</a> 
                                    <span class="citationText" aria-hidden="true">PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prévention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation. 2005 Jul 19;112(3):416-22.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://circ.ahajournals.org/content/112/3/416.long
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/16009794?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;Occlusion of the IVC affects approximately 22% of patients at 5 years and 33% at 9 years, regardless of the use and duration of anticoagulation.
                                    <span class="reference"> 
                                    <a href="#referencePop193" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[193]</a> 
                                    <span class="citationText" aria-hidden="true">PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prévention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation. 2005 Jul 19;112(3):416-22.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://circ.ahajournals.org/content/112/3/416.long
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/16009794?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Post-filter anticoagulation should be considered on a case-by-case basis according to relative and absolute contraindications.
                                    <span class="reference"> 
                                    <a href="#referencePop194" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[194]</a> 
                                    <span class="citationText" aria-hidden="true">Decousus H, Leizorovicz A, Parent F, et al; Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med. 1998 Feb 12;338(7):409-15.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://www.nejm.org/doi/10.1056/NEJM199802123380701
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/9459643?tool=bestpractice.com
                                    </span>
                                    </span>
                                    Anticoagulation should be initiated if the contraindication resolves or if a risk/benefit analysis suggests this to be a reasonable course.
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;When retrievable filters are used, they should be removed as soon as it is safe to use anticoagulants.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                              </div>
                              <!--/.panel-body -->
                           </section>
                        </div>
                        <!--/.panel-body -->
                     </div>
                     <!-- /.panel-group -->
                  </div>
               </div>
            </div>
            <div class="card">
               <div class="card-block">
                  <div class="container">
                     <div class="rowHead" id="ongoing">
                        <div class="col-md-12">
                           ONGOING
                        </div>
                     </div>
                     <div class="panel">
                        <div class="panel-heading">
                           <h3>
                              <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" id="patientGroup-1-0">
                              <span>confirmed PE: no underlying malignancy, non-pregnant, no contraindication to anticoagulation</span>
                              <span class="hidden-sm-down">
                              <span class="msg">VIEW ALL</span>
                              <span class="material-icons" role="button"><span></span><span></span></span>
                              </span>
                              </a>
                           </h3>
                        </div>
                        <!--/.panel-heading -->
                        <div class="panel-body">
                           <section class="panel-group">
                              <div class="panel-header">
                                 <p class="panel-title"> 
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_1_0_0" aria-controls="panel_1_0_0" aria-expanded="false">
                                    <span class="titles-wrap col-md-12">
                                    <span class="title-02">
                                    <span class="title-03 col-md-1">
                                    1st line
                                    <span class="noShow">&nbsp;–&nbsp;</span>
                                    </span>
                                    <span class="title-04">
                                    <span class="material-icons"><span></span><span></span></span>
                                    <span class="txtwrap no-icon">anticoagulation</span>
                                    </span>
                                    </span>
                                    </span>
                                    </a>
                                 </p>
                              </div>
                              <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_1_0_0" id="panel_1_0_0" aria-expanded="false">
                                 <!--  ADJUNCT/PLUS DISCLAIMER -->
                                 <div class="treatment-wrap">
                                    <!-- display regimens -->
                                    <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                    <h4>Primary options</h4>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_0f8c4ada-cd84-4c04-8860-01a81e07c1f9_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">rivaroxaban</a><span>: </span><span>20 mg orally once daily; 10 mg orally once daily after completing at least 6 months treatment</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                    <p class="small-or">OR</p>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_aff9d94e-1579-4f56-acb7-73775d12d818_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">apixaban</a><span>: </span><span>5 mg orally twice daily; 2.5 mg orally twice daily after completing at least 6 months treatment</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                    <p class="small-or">OR</p>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_6402d40a-aa86-4def-a6af-9d56b0e8ef3e_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dabigatran</a><span>: </span><span>150 mg orally twice daily</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                    <p class="small-or">OR</p>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_4b33f194-29da-4239-aae9-c1746e2bda94_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">edoxaban</a><span>: </span><span>body weight ≤60 kg: 30 mg orally once daily; body weight &gt;60 kg: 60 mg orally once daily</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                    <p class="small-or">OR</p>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_3984222a-c42a-4f8a-bff1-f99645ade85d_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">enoxaparin</a><span>: </span><span>1 mg/kg subcutaneously twice daily; or 1.5 mg/kg subcutaneously once daily</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                    <p class="small-or">OR</p>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_d4ccd444-8501-447d-848f-bc97c03774ba_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dalteparin</a><span>: </span><span>200 units/kg subcutaneously once daily, maximum 18,000 units/dose; or 100 units/kg subcutaneously every 12 hours</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                    <p class="small-or">OR</p>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">warfarin</a><span>: </span><span>5 mg orally once daily initially, adjust according to INR (goal INR is 2 to 3)</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                 </div>
                                 <!--/.treatment-wrap-->
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Recommendations for continuation of anticoagulant therapy vary by patient group. In patients who receive continued anticoagulation therapy, there is usually no need to change the initial oral anticoagulant.
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;Continued anticoagulant therapy may be for a pre-determined timeframe (e.g., 3 months) or extended (with no scheduled stop date). 
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Evidence from studies of ≥6 months’ duration suggests that there are no differences between direct-acting oral anticoagulants and conventional anticoagulation for the management of PE.
                                    <span class="reference"> 
                                    <a href="#referencePop209" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[209]</a> 
                                    <span class="citationText" aria-hidden="true">Robertson L, Kesteven P, McCaslin JE. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism. Cochrane Database Syst Rev. 2015 Dec 4;(12):CD010957.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD010957.pub2/full
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26636644?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop210" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[210]</a> 
                                    <span class="citationText" aria-hidden="true">Becattini C, Agnelli G. Risk stratification and management of acute pulmonary embolism. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):404-12.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://asheducationbook.hematologylibrary.org/content/2016/1/404.long
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/27913508?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" data-trigger="click focus" data-toggle="popover" class="cochranePop" data-original-title="" title="">
                                    [ <img src="../images/cca-cochrane-logo-inline.png" alt="Cochrane Clinical Answers logo"> ] 
                                    </a>
                                    <span class="ccaTitle" aria-hidden="true">How do oral direct thrombin inhibitors and oral factor Xa inhibitors compare with standard anticoagulation for the treatment of pulmonary embolism?</span>
                                    <span class="ccaUrl" aria-hidden="true">/cca.html?targetUrl=https://cochranelibrary.com/cca/doi/10.1002/cca.1439/full</span>
                                    <span class="ccaHrefText" aria-hidden="true">Show me the answer</span>
                                    </span>
                                    &nbsp;In all patients who receive extended anticoagulant therapy, its continued use should be reassessed at periodic intervals (such as annually).
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    When assessing bleeding risk, the following factors should be considered:
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;age &gt;65 years, previous bleeding, cancer, renal failure, liver failure, thrombocytopenia, previous stroke, diabetes mellitus, anaemia, antiplatelet therapy, poor anticoagulant control, comorbidity with reduced functional capacity, recent surgery, frequent falls, alcohol abuse, use of non-steroidal anti-inflammatory drugs.
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Patients with none of these risk factors are considered low risk; one risk factor renders a patient moderate risk; and two or more risk factors renders a patient high risk.
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Guidelines recommend the following oral anticoagulant treatment durations: PE provoked by surgery: 3 months; PE provoked by a non-surgical transient risk factor: 3 months; unprovoked PE with low or moderate bleeding risk: extended anticoagulant therapy (i.e., no scheduled stop date) with periodic risk assessment to review risk-benefit ratio; unprovoked PE with high bleeding risk: 3 months.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                              </div>
                              <!--/.panel-body -->
                           </section>
                        </div>
                        <!--/.panel-body -->
                     </div>
                     <div class="panel">
                        <div class="panel-heading">
                           <h3>
                              <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" id="patientGroup-1-1">
                              <span>confirmed PE: malignancy, no contraindication to anticoagulation</span>
                              <span class="hidden-sm-down">
                              <span class="msg">VIEW ALL</span>
                              <span class="material-icons" role="button"><span></span><span></span></span>
                              </span>
                              </a>
                           </h3>
                        </div>
                        <!--/.panel-heading -->
                        <div class="panel-body">
                           <section class="panel-group">
                              <div class="panel-header">
                                 <p class="panel-title"> 
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_1_1_0" aria-controls="panel_1_1_0" aria-expanded="false">
                                    <span class="titles-wrap col-md-12">
                                    <span class="title-02">
                                    <span class="title-03 col-md-1">
                                    1st line
                                    <span class="noShow">&nbsp;–&nbsp;</span>
                                    </span>
                                    <span class="title-04">
                                    <span class="material-icons"><span></span><span></span></span>
                                    <span class="txtwrap no-icon">low molecular weight heparin (LMWH)</span>
                                    </span>
                                    </span>
                                    </span>
                                    </a>
                                 </p>
                              </div>
                              <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_1_1_0" id="panel_1_1_0" aria-expanded="false">
                                 <!--  ADJUNCT/PLUS DISCLAIMER -->
                                 <div class="treatment-wrap">
                                    <!-- display regimens -->
                                    <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                    <h4>Primary options</h4>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_3984222a-c42a-4f8a-bff1-f99645ade85d_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">enoxaparin</a><span>: </span><span>1 mg/kg subcutaneously twice daily; or 1.5 mg/kg subcutaneously once daily</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                    <p class="small-or">OR</p>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_d4ccd444-8501-447d-848f-bc97c03774ba_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dalteparin</a><span>: </span><span>200 units/kg subcutaneously once daily for 1 month, followed by 150 units/kg once daily for 5 months, maximum 18,000 units/dose</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                 </div>
                                 <!--/.treatment-wrap-->
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    LMWH is preferred over a vitamin K antagonist (VKA), dabigatran, rivaroxaban, apixaban, or edoxaban for the treatment of PE in patients with active malignancy.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop211" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[211]</a> 
                                    <span class="citationText" aria-hidden="true">Lyman GH, Bohlke K, Khorana AA, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol. 2015 Feb 20;33(6):654-6.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://ascopubs.org/doi/full/10.1200/JCO.2014.59.7351
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25605844?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    European guidelines recommend anticoagulant therapy for a period of 3 to 6 months;
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;the American College of Chest Physicians recommends extended anticoagulant therapy (i.e., no scheduled stop date).
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    LMWH is more effective than a VKA in patients with cancer (moderate-quality evidence), 
                                    <span class="reference"> 
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" data-trigger="click focus" data-toggle="popover" class="cochranePop" data-original-title="" title="">
                                    [ <img src="../images/cca-cochrane-logo-inline.png" alt="Cochrane Clinical Answers logo"> ] 
                                    </a>
                                    <span class="ccaTitle" aria-hidden="true">How do low‐molecular‐weight heparin (LMWH), vitamin K agonists (VKAs), and direct oral anticoagulants (DOACs) compare for treatment of venous thromboembolism (VTE) in people with cancer?</span>
                                    <span class="ccaUrl" aria-hidden="true">/cca.html?targetUrl=https://cochranelibrary.com/cca/doi/10.1002/cca.2255/full</span>
                                    <span class="ccaHrefText" aria-hidden="true">Show me the answer</span>
                                    </span>
                                    is therapeutically reliable in patients for whom oral therapy may be inappropriate (e.g., vomiting), and is easier to adjust/withhold if thrombocytopenia develops or an invasive intervention is needed.
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;Furthermore, patients with cancer treated with a VKA may be difficult to maintain within the therapeutic range, and experience substantial rates of recurrence.
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                              </div>
                              <!--/.panel-body -->
                           </section>
                        </div>
                        <!--/.panel-body -->
                     </div>
                     <div class="panel">
                        <div class="panel-heading">
                           <h3>
                              <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" id="patientGroup-1-2">
                              <span>confirmed PE: pregnant, no contraindication to anticoagulation</span>
                              <span class="hidden-sm-down">
                              <span class="msg">VIEW ALL</span>
                              <span class="material-icons" role="button"><span></span><span></span></span>
                              </span>
                              </a>
                           </h3>
                        </div>
                        <!--/.panel-heading -->
                        <div class="panel-body">
                           <section class="panel-group">
                              <div class="panel-header">
                                 <p class="panel-title"> 
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_1_2_0" aria-controls="panel_1_2_0" aria-expanded="false">
                                    <span class="titles-wrap col-md-12">
                                    <span class="title-02">
                                    <span class="title-03 col-md-1">
                                    1st line
                                    <span class="noShow">&nbsp;–&nbsp;</span>
                                    </span>
                                    <span class="title-04">
                                    <span class="material-icons"><span></span><span></span></span>
                                    <span class="txtwrap no-icon">low molecular weight heparin (LMWH)</span>
                                    </span>
                                    </span>
                                    </span>
                                    </a>
                                 </p>
                              </div>
                              <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_1_2_0" id="panel_1_2_0" aria-expanded="false">
                                 <!--  ADJUNCT/PLUS DISCLAIMER -->
                                 <div class="treatment-wrap">
                                    <!-- display regimens -->
                                    <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                    <h4>Primary options</h4>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_3984222a-c42a-4f8a-bff1-f99645ade85d_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">enoxaparin</a><span>: </span><span>1 mg/kg subcutaneously twice daily; or 1.5 mg/kg subcutaneously once daily</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                    <p class="small-or">OR</p>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_d4ccd444-8501-447d-848f-bc97c03774ba_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dalteparin</a><span>: </span><span>200 units/kg subcutaneously once daily, maximum 18,000 units/dose; or 100 units/kg subcutaneously every 12 hours</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                 </div>
                                 <!--/.treatment-wrap-->
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    LMWH should be administered for at least 6 weeks postnatally in women at high risk of postnatal venous thromboembolism, and for a minimum overall treatment duration of 3 months.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop212" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[212]</a> 
                                    <span class="citationText" aria-hidden="true">Royal College of Obstetricians and Gynaecologists. Reducing the risk of venous thromboembolism during pregnancy and the puerperium. Green-top guideline No. 37a. Apr 2015 [internet publication].</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://www.rcog.org.uk/globalassets/documents/guidelines/gtg-37a.pdf
                                    </span>
                                    </span>
                                    &nbsp;
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Other anticoagulants, including vitamin K antagonists (VKAs), may cross the placenta.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    VKAs are an option for breastfeeding mothers.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                              </div>
                              <!--/.panel-body -->
                           </section>
                        </div>
                        <!--/.panel-body -->
                     </div>
                     <div class="panel">
                        <div class="panel-heading">
                           <h3>
                              <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" id="patientGroup-1-3">
                              <span>confirmed PE: severe renal impairment, no contraindication to anticoagulation</span>
                              <span class="hidden-sm-down">
                              <span class="msg">VIEW ALL</span>
                              <span class="material-icons" role="button"><span></span><span></span></span>
                              </span>
                              </a>
                           </h3>
                        </div>
                        <!--/.panel-heading -->
                        <div class="panel-body">
                           <section class="panel-group">
                              <div class="panel-header">
                                 <p class="panel-title"> 
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_1_3_0" aria-controls="panel_1_3_0" aria-expanded="false">
                                    <span class="titles-wrap col-md-12">
                                    <span class="title-02">
                                    <span class="title-03 col-md-1">
                                    1st line
                                    <span class="noShow">&nbsp;–&nbsp;</span>
                                    </span>
                                    <span class="title-04">
                                    <span class="material-icons"><span></span><span></span></span>
                                    <span class="txtwrap no-icon">vitamin K antagonist (VKA)</span>
                                    </span>
                                    </span>
                                    </span>
                                    </a>
                                 </p>
                              </div>
                              <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_1_3_0" id="panel_1_3_0" aria-expanded="false">
                                 <!--  ADJUNCT/PLUS DISCLAIMER -->
                                 <div class="treatment-wrap">
                                    <!-- display regimens -->
                                    <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                    <h4>Primary options</h4>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_1f043ef5-6686-4b38-a018-9dea67de1e36_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">warfarin</a><span>: </span><span>5 mg orally once daily initially, adjust according to INR (goal INR is 2 to 3)</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                 </div>
                                 <!--/.treatment-wrap-->
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    The American College of Chest Physicians recommends a VKA for patients with severe renal impairment (i.e., creatinine clearance &lt;30 mL/minute).
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Health professionals should refer to the label and/or local formularies before prescribing a direct-acting oral anticoagulant for a patient with renal impairment.
                                 </p>
                              </div>
                              <!--/.panel-body -->
                           </section>
                        </div>
                        <!--/.panel-body -->
                     </div>
                     <div class="panel">
                        <div class="panel-heading">
                           <h3>
                              <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" id="patientGroup-1-4">
                              <span>confirmed PE: hepatic impairment and coagulopathy, no contraindication to anticoagulation</span>
                              <span class="hidden-sm-down">
                              <span class="msg">VIEW ALL</span>
                              <span class="material-icons" role="button"><span></span><span></span></span>
                              </span>
                              </a>
                           </h3>
                        </div>
                        <!--/.panel-heading -->
                        <div class="panel-body">
                           <section class="panel-group">
                              <div class="panel-header">
                                 <p class="panel-title"> 
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_1_4_0" aria-controls="panel_1_4_0" aria-expanded="false">
                                    <span class="titles-wrap col-md-12">
                                    <span class="title-02">
                                    <span class="title-03 col-md-1">
                                    1st line
                                    <span class="noShow">&nbsp;–&nbsp;</span>
                                    </span>
                                    <span class="title-04">
                                    <span class="material-icons"><span></span><span></span></span>
                                    <span class="txtwrap no-icon">low molecular weight heparin (LMWH)</span>
                                    </span>
                                    </span>
                                    </span>
                                    </a>
                                 </p>
                              </div>
                              <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_1_4_0" id="panel_1_4_0" aria-expanded="false">
                                 <!--  ADJUNCT/PLUS DISCLAIMER -->
                                 <div class="treatment-wrap">
                                    <!-- display regimens -->
                                    <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                    <h4>Primary options</h4>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_3984222a-c42a-4f8a-bff1-f99645ade85d_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">enoxaparin</a><span>: </span><span>1 mg/kg subcutaneously twice daily; or 1.5 mg/kg subcutaneously once daily</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                    <p class="small-or">OR</p>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_d4ccd444-8501-447d-848f-bc97c03774ba_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dalteparin</a><span>: </span><span>200 units/kg subcutaneously once daily, maximum 18,000 units/dose; or 100 units/kg subcutaneously every 12 hours</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                 </div>
                                 <!--/.treatment-wrap-->
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    The American College of Chest Physicians recommends LMWH in this patient population.
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Health professionals should refer to the label and/or local formularies before prescribing a direct-acting oral anticoagulant for a patient with hepatic impairment.
                                 </p>
                              </div>
                              <!--/.panel-body -->
                           </section>
                        </div>
                        <!--/.panel-body -->
                     </div>
                     <div class="panel">
                        <div class="panel-heading">
                           <h3>
                              <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" id="patientGroup-1-5">
                              <span>confirmed PE: recurrent PE</span>
                              <span class="hidden-sm-down">
                              <span class="msg">VIEW ALL</span>
                              <span class="material-icons" role="button"><span></span><span></span></span>
                              </span>
                              </a>
                           </h3>
                        </div>
                        <!--/.panel-heading -->
                        <div class="panel-body">
                           <section class="panel-group">
                              <div class="panel-header">
                                 <p class="panel-title"> 
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_1_5_0" aria-controls="panel_1_5_0" aria-expanded="false">
                                    <span class="titles-wrap col-md-12">
                                    <span class="title-02">
                                    <span class="title-03 col-md-1">
                                    1st line
                                    <span class="noShow">&nbsp;–&nbsp;</span>
                                    </span>
                                    <span class="title-04">
                                    <span class="material-icons"><span></span><span></span></span>
                                    <span class="txtwrap no-icon">low molecular weight heparin (LMWH)</span>
                                    </span>
                                    </span>
                                    </span>
                                    </a>
                                 </p>
                              </div>
                              <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_1_5_0" id="panel_1_5_0" aria-expanded="false">
                                 <!--  ADJUNCT/PLUS DISCLAIMER -->
                                 <div class="treatment-wrap">
                                    <!-- display regimens -->
                                    <!-- <h4 th:text="${tier.key} + ' options'"></h4> -->
                                    <h4>Primary options</h4>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_3984222a-c42a-4f8a-bff1-f99645ade85d_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">enoxaparin</a><span>: </span><span>consult specialist for guidance on dose</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                    <p class="small-or">OR</p>
                                    <div class="treatment-box">
                                       <p>
                                          <a href="#drugDbPop_d4ccd444-8501-447d-848f-bc97c03774ba_en-gb" data-trigger="click focus" class="drugDbPop" data-toggle="popover" data-original-title="" title="">dalteparin</a><span>: </span><span>consult specialist for guidance on dose</span>
                                       </p>
                                    </div>
                                    <!--/.treatment-box-->
                                 </div>
                                 <!--/.treatment-wrap-->
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Recurrent VTE is unusual among patients receiving therapeutic-dose anticoagulant therapy.
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;In addition to definitively establishing the presence of recurrent PE, consideration should be given to compliance with anticoagulant therapy or the presence of underlying malignancy.
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    American College of Chest Physicians guidelines recommend a temporary switch to LMWH (for at least 1 month) for patients with recurrent PE who are thought to be compliant with a non-LMWH anticoagulant (or within the therapeutic range if receiving VKA therapy).
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;An increased dose of LMWH (one quarter to one third) is appropriate for patients with recurrent PE who have been receiving LMWH.
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    For patients who are no longer receiving anticoagulant therapy and experience a second unprovoked PE, guidelines recommend the following anticoagulant treatment durations: low or moderate bleeding risk: extended anticoagulant therapy with periodic reassessment to review risk-benefit ratio; high bleeding risk: 3 months.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                                    <span class="citationText" aria-hidden="true">Kearon C, Akl EA, Ornelas J, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016 Feb;149(2):315-52.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://journal.chestnet.org/article/S0012-3692(15)00335-9/fulltext
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/26867832?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                              </div>
                              <!--/.panel-body -->
                           </section>
                           <section class="panel-group">
                              <div class="panel-header">
                                 <p class="panel-title"> 
                                    <a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" role="tab header" id="tab_1_5_1" aria-controls="panel_1_5_1" aria-expanded="false">
                                    <span class="titles-wrap col-md-12">
                                    <span class="title-02">
                                    <span class="title-03 col-md-1">
                                    Adjunct
                                    <span class="noShow">&nbsp;–&nbsp;</span>
                                    </span>
                                    <span class="title-04">
                                    <span class="material-icons"><span></span><span></span></span>
                                    <span class="txtwrap no-icon">venous filter</span>
                                    </span>
                                    </span>
                                    </span>
                                    </a>
                                 </p>
                              </div>
                              <div class="panel-content col-md-10" role="tabpanel" aria-labelledby="tab_1_5_1" id="panel_1_5_1" aria-expanded="false">
                                 <!--  ADJUNCT/PLUS DISCLAIMER -->
                                 <p class="w-75 smPopTxt">Treatment recommended for SOME patients in selected patient group</p>
                                 <!--/.treatment-wrap-->
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    An inferior vena cava (IVC) filter can be placed in patients with confirmed recurrent PE despite adequate anticoagulation.
                                    <span class="reference"> 
                                    <a href="#referencePop76" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[76]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Torbicki A, Agnelli G, et al; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    https://academic.oup.com/eurheartj/article/35/43/3033/503581
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/25173341?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop184" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[184]</a> 
                                    <span class="citationText" aria-hidden="true">Konstantinides SV, Barco S. Systemic thrombolytic therapy for acute pulmonary embolism: who is a candidate? Semin Respir Crit Care Med. 2017 Feb;38(1):56-65.</span> 
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/28208199?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                                 <p class="w-75">
                                    <!-- col-md-9 -->
                                    Complications associated with permanent IVC filters are common, although they are rarely fatal.
                                    <span class="reference"> 
                                    <a href="#referencePop191" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[191]</a> 
                                    <span class="citationText" aria-hidden="true">Muriel A, Jiménez D, Aujesky D, et al. Survival effects of inferior vena cava filter in patients with acute symptomatic venous thromboembolism and a significant bleeding risk. J Am Coll Cardiol. 2014 Apr 29;63(16):1675-83.</span> 
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/24576432?tool=bestpractice.com
                                    </span>
                                    </span>
                                    &nbsp;Overall, early complications (including insertion-site thrombosis) occur in approximately 10% of patients. Late complications are more frequent and include recurrent DVT (approximately 20% of patients) and post-thrombotic syndrome (up to 40% of patients).
                                    <span class="reference"> 
                                    <a href="#referencePop192" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[192]</a> 
                                    <span class="citationText" aria-hidden="true">Rajasekhar A, Streiff MB. Vena cava filters for management of venous thromboembolism: a clinical review. Blood Rev. 2013 Sep;27(5):225-41.</span> 
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/23932118?tool=bestpractice.com
                                    </span>
                                    </span>
                                    <span class="reference"> 
                                    <a href="#referencePop193" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[193]</a> 
                                    <span class="citationText" aria-hidden="true">PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prévention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation. 2005 Jul 19;112(3):416-22.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://circ.ahajournals.org/content/112/3/416.long
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/16009794?tool=bestpractice.com
                                    </span>
                                    </span>
                                    Occlusion of the IVC affects approximately 22% of patients at 5 years and 33% at 9 years, regardless of the use and duration of anticoagulation.
                                    <span class="reference"> 
                                    <a href="#referencePop193" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[193]</a> 
                                    <span class="citationText" aria-hidden="true">PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prévention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation. 2005 Jul 19;112(3):416-22.</span> 
                                    <span class="citationFullTextUrl" aria-hidden="true">
                                    http://circ.ahajournals.org/content/112/3/416.long
                                    </span>
                                    <span class="referenceUniqueId" aria-hidden="true">
                                    http://www.ncbi.nlm.nih.gov/pubmed/16009794?tool=bestpractice.com
                                    </span>
                                    </span>
                                 </p>
                              </div>
                              <!--/.panel-body -->
                           </section>
                        </div>
                        <!--/.panel-body -->
                     </div>
                     <!-- /.panel-group -->
                  </div>
               </div>
            </div>
         </div>
         <div class="card-block disclaimer">
            <p><span>Use of this content is subject to our <a href="https://bestpractice.bmj.com/info/disclaimer/" target="_blank">disclaimer</a> </span></p>
         </div>
         <script type="text/javascript">//<![CDATA[
            var drugDatabases = ["AHFS","BNF","BNFC","MARTINDALE","MICROMEDEX"];
            var drugMappings = {"b3fb3286-271c-47f6-ae52-1bd3958b1e9b":{"BNFC":"844811582","AHFS":"382789","BNF":"844811582","MARTINDALE":"2041-c"},"46d9672e-3313-452d-9bfd-a4ddf90b32f3":{"BNFC":"338844366","AHFS":"382749","BNF":"338844366","MARTINDALE":"9506-x"},"d4ccd444-8501-447d-848f-bc97c03774ba":{"BNFC":"694891763","AHFS":"396006","BNF":"694891763","MARTINDALE":"14676-j"},"88583afa-6bbd-4755-a21e-c63ab12370f0":{"AHFS":"301057","MARTINDALE":"17311-s"},"4866ce04-4d68-4b50-83f4-66283ea52c07":{"BNFC":"347445885","AHFS":"382826","BNF":"347445885","MARTINDALE":"11401-s"},"0f8c4ada-cd84-4c04-8860-01a81e07c1f9":{"AHFS":"312005","BNF":"758974083","MARTINDALE":"22005-r"},"3984222a-c42a-4f8a-bff1-f99645ade85d":{"BNFC":"190424995","AHFS":"393016","BNF":"190424995","MARTINDALE":"13424-s"},"4b33f194-29da-4239-aae9-c1746e2bda94":{"AHFS":"315041","BNF":"142886536","MARTINDALE":"25433-t"},"aff9d94e-1579-4f56-acb7-73775d12d818":{"AHFS":"313017","BNF":"379487049","MARTINDALE":"24489-b"},"1f043ef5-6686-4b38-a018-9dea67de1e36":{"BNFC":"107604022","AHFS":"382277","BNF":"107604022","MARTINDALE":"21515-l"},"6402d40a-aa86-4def-a6af-9d56b0e8ef3e":{"AHFS":"311009","BNF":"860832161","MARTINDALE":"20786-b"},"89dc308c-7daa-4c1f-a0c4-829a581f1936":{"BNFC":"169791712","AHFS":"389001","BNF":"169791712","MARTINDALE":"16956-z"},"a37dcf97-a50b-4776-ad01-6fd4a31bb295":{"BNFC":"829952202","AHFS":"382861","BNF":"829952202","MARTINDALE":"2052-t"},"a4adb6a6-1e28-4057-9789-361aa3c914b8":{"AHFS":"302012","BNF":"724890658","MARTINDALE":"20172-x"}};
            //]]>
         </script>
      </main>
      <!-- set the messages country code variable from region to be used from i18 plugin. Setting here so it's available in all pages -->
      <script>
         /*<![CDATA[*/
         
         var messagesCountryCode = "en_GB";
         /*]]>*/
           
      </script>
      <aside id="panel-nhs" class="card-block">
         <div id="access" class="col-sm-6">
            <div class="row">
               <div class="col-md-6">
                  <p>Access provided by:</p>
               </div>
               <div class="col-md-6">
                  <img src="../images/bmj-logo.png" alt="BMJ Group (Online access from BMA House)">
               </div>
            </div>
         </div>
      </aside>
      <footer id="footer">
         <div class="container">
            <div class="row">
               <nav class="col-md-9" role="navigation">
                  <div class="row">
                     <dl class="col-md-4" role="menu">
                        <dt>Browse</dt>
                        <dd><a href="https://bestpractice.bmj.com/">Home</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/recent-updates">Recent updates</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/specialties">Specialties</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/calculators">Calculators</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/patient-leaflets">Patient leaflets</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/procedural-videos">Procedural videos</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/evidence">Evidence</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/drugs">Drugs</a></dd>
                     </dl>
                     <!-- logged-in individual or institutional user -->
                     <!-- unknown user -->
                     <!--institutional user not logged in-->
                     <dl class="col-md-4" role="menu">
                        <dt>Services</dt>
                        <dd><a href="https://bestpractice.bmj.com/login">Log in</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/registration">Create an account</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/getting-started/" target="_blank">Getting started</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/faq/" target="_blank">FAQs</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/benefits-features/earn-cme-points/" target="_blank">About CME/CPD</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/benefits-features/" target="_blank">About us</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/app/" target="_blank">Mobile app</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/contact-us/" target="_blank">Contact us</a></dd>
                        <dd>
                           <a href="https://myaccount.bmj.com/myaccount/registration.html?regService=bestpractice-email-alert&amp;fwdUrl=https://bestpractice.bmj.com">
                           Sign up for email alerts
                           </a>
                        </dd>
                     </dl>
                     <dl class="col-md-4" role="menu">
                        <dt>Legal</dt>
                        <dd><a href="https://bestpractice.bmj.com/info/disclaimer/" target="_blank">Disclaimer</a></dd>
                        <dd><a href="https://www.bmj.com/company/legal-information/" target="_blank">Terms and conditions</a></dd>
                        <dd><a href="https://www.bmj.com/company/your-privacy/" target="_blank">Privacy notice</a></dd>
                        <dd><a href="https://www.bmj.com/company/your-privacy/cookies-policy/" target="_blank">Cookie policy</a></dd>
                     </dl>
                  </div>
                  <!-- row -->
               </nav>
               <div class="col-md-3">
                  <ul>
                     <li><a target="_blank" href="https://www.facebook.com/BMJBestPractice"><img alt="Facebook Logo" title="Facebook" src="../images/facebook-64.png" width="60" height="60"></a></li>
                     <li><a target="_blank" href="https://twitter.com/BMJBestPractice"><img alt="Twiter Logo" title="Twitter" src="../images/twitter-64.png" width="60" height="60"></a></li>
                     <li><a target="_blank" href="https://www.linkedin.com/showcase/15218227/"><img alt="LinkedIn Logo" title="LinkedIn" src="../images/linkedIn_logo_circle.png" width="60" height="60"></a></li>
                     <li><a target="_blank" href="https://www.youtube.com/channel/UCt72GZ0cPXpk4EzgFhdWYdQ"><img alt="Youtube Logo" title="YouTube" src="../images/youtube-64.png" width="60" height="60"></a></li>
                  </ul>
                  <p class="copyright mt-3"><small>© BMJ Publishing Group 2018</small></p>
                  <p class="issn"><small>ISSN 2515-9615</small></p>
               </div>
            </div>
            <!-- row -->  
         </div>
         <!-- container -->    
      </footer>
      <div class="container modal-registration-form" aria-hidden="true">
         <div id="feedbackContainer" class="modal fade" tabindex="-1" role="dialog" aria-labelledby="ModalFeedbackLabel" aria-hidden="true">
            <div class="modal-dialog modal-lg" role="document">
               <div class="modal-content pb-3">
                  <div class="modal-header">
                     <div class="row">
                        <div class="col-md-12">
                           <h2>Help us improve <abbr>BMJ</abbr> Best Practice</h2>
                           <button type="button" class="close" data-dismiss="modal" aria-label="Close">
                           <span aria-hidden="true">×</span>
                           </button>
                        </div>
                        <div class="col-md-12">
                           <p>Please complete all fields.</p>
                        </div>
                     </div>
                  </div>
                  <div class="modal-body">
                     <div class="row">
                        <div class="col-md-12">
                           <form id="feedbackForm" action="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#" novalidate="novalidate">
                              <div class="row">
                                 <div class="col-md-6">
                                    <div class="form-group floating-label">
                                       <label for="feedbackName">Name</label> 
                                       <input id="feedbackName" class="form-control" name="feedbackName" type="text">
                                    </div>
                                 </div>
                                 <div class="col-md-6">
                                    <div class="form-group floating-label">
                                       <label for="feedbackEmail">Email</label> 
                                       <input id="feedbackEmail" class="form-control" name="feedbackEmail" type="email" value="">
                                    </div>
                                 </div>
                              </div>
                              <div class="row">
                                 <div class="col-md-12">
                                    <h2 id="feedbackPageTitle" class="h3">Page: Pulmonary embolism - Treatment algorithm | BMJ Best Practice</h2>
                                 </div>
                              </div>
                              <input id="feedbackPage" name="feedbackPage" type="hidden" value="Pulmonary embolism - Treatment algorithm | BMJ Best Practice">
                              <div class="row">
                                 <div class="col-md-4">
                                    <p>I have some feedback on:</p>
                                    <fieldset class="form-group" role="radiogroup">
                                       <legend>Feedback on: </legend>
                                       <label for="feedOn01"><input id="feedOn01" type="radio" name="feedbackOn" value="This page" checked="checked">&nbsp;This page</label>
                                       <label for="feedOn02"><input id="feedOn02" type="radio" name="feedbackOn" value="This website">&nbsp;The website in general</label>
                                       <label for="feedOn03"><input id="feedOn03" type="radio" name="feedbackOn" value="Something else">&nbsp;Something else</label>
                                    </fieldset>
                                 </div>
                                 <div class="col-md-8">
                                    <div class="form-group floating-label textarea">
                                       <label for="feedbackContent">I have some feedback on:</label>
                                       <textarea id="feedbackContent" name="feedbackContent"></textarea>
                                    </div>
                                 </div>
                              </div>
                              <div class="row">
                                 <div class="col-md-12">
                                    <p>We will respond to all feedback.</p>
                                 </div>
                              </div>
                              <div class="row">
                                 <div class="col-md-12">
                                    <button id="feedbackSubmit" type="submit" class="btn btn-secondary btn-lg">
                                    <span id="spinner2" class="progress-circular-inner progress-circular-left"></span>
                                    <span id="btnText2">Submit Feedback</span>
                                    </button>
                                 </div>
                              </div>
                              <div class="row smTxt">
                                 <div class="col-md-12">
                                    <p>For any urgent enquiries please contact our customer services team who are ready to help with any problems.</p>
                                 </div>
                              </div>
                              <div class="row smTxt">
                                 <div class="col-md-3">
                                    <p><b>Phone:</b> +44 (0) 207 111 1105</p>
                                 </div>
                                 <div class="col-md-3">
                                    <p><b>Email: </b> <a href="mailto:support@bmj.com">support@bmj.com</a></p>
                                 </div>
                              </div>
                           </form>
                        </div>
                     </div>
                  </div>
               </div>
            </div>
         </div>
         <div class="modal fade" id="editComo" tabindex="-1" role="dialog" aria-labelledby="editComo" aria-hidden="true" style="display: none;">
               <div class="modal-dialog" role="document" style="max-width: 50rem;">
                  <div class="modal-content">
                     <div class="modal-header" style="background: #fff; margin-top: 1rem;">
                        <h2 class="modal-title" id="exampleModalLabel" style="color: #333;">
                           <span style="font-size: 50px;" class="material-icons">
                                 <svg version="1.1" class="co-morbidity-icon-pink" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 30 30" enable-background="new 0 0 30 30" xml:space="preserve">
                                    <g>
                                       <g>
                                          <path fill="#C50084" d="M13.403,11.642c1.223-2.384,3.7-4.019,6.564-4.019c2.285,0,4.326,1.039,5.679,2.669l4.119-4.119
                                             c-2.416-2.68-5.905-4.375-9.798-4.375c-4.644,0-8.721,2.404-11.074,6.029C10.865,8.429,12.489,9.826,13.403,11.642z"></path>
                                          <path fill="#C50084" d="M19.967,22.378c-2.864,0-5.341-1.635-6.564-4.019c-0.914,1.815-2.538,3.212-4.511,3.815
                                             c2.353,3.626,6.43,6.029,11.074,6.029c3.893,0,7.381-1.695,9.798-4.375l-4.119-4.119C24.293,21.339,22.251,22.378,19.967,22.378z"></path>
                                          <g>
                                             <circle fill="#C50084" cx="6.736" cy="15" r="6.5"></circle>
                                          </g>
                                       </g>
                                       <polygon fill="#FFFFFF" points="11.207,14 7.707,14 7.707,10.5 5.707,10.5 5.707,14 2.207,14 2.207,16 5.707,16 5.707,19.5 
                                          7.707,19.5 7.707,16 11.207,16 	"></polygon>
                                    </g>
                                    </svg>
                              </span> Add your patient's comorbidities</h2>
                        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
                        <span aria-hidden="true" style="color: #333 !important; font-size: 28px;">×</span>
                        </button>
                     </div>
                     <div class="modal-body">
                        <p>Treatment recommendations for acute pancreatitis will change dependent on your patient's comorbitities</p>
                        <div class="row">
                           <div class="col-md-12" style="margin-bottom: 0.75rem;">
                              <h3>Select comorbidities</h3>
                           </div>
                           <div class="col-md-6">
                              <div class="card">
                                 <ul class="list-group list-group-flush">
                                    <li class="list-group-item"><label for="hypertension" class="custom-control custom-checkbox">
                                       <input type="checkbox" name="comorbidity" id="hypertension" class="comotype custom-control-input" value="Hypertension"> 
                                       <span class="custom-control-indicator"></span> 
                                       <span class="custom-control-description">Hypertension</span>
                                       </label>
                                    </li>
                                    <li class="list-group-item"><label for="cad" class="comotype custom-control custom-checkbox">
                                       <input type="checkbox" name="comorbidity" id="cad" class="custom-control-input" value="Coronary artery disease"> 
                                       <span class="custom-control-indicator"></span> 
                                       <span class="custom-control-description">Coronary artery disease</span>
                                       </label>
                                    </li>
                                    <li class="list-group-item"><label for="heartfailure" class="custom-control custom-checkbox">
                                       <input type="checkbox" name="comorbidity" id="heartfailure" class="comotype custom-control-input" value="Heart failure"> 
                                       <span class="custom-control-indicator"></span> 
                                       <span class="custom-control-description">Heart failure</span>
                                       </label>
                                    </li>
                                    <li class="list-group-item"><label for="stroke" class="comotype custom-control custom-checkbox">
                                       <input type="checkbox" name="comorbidity" id="stroke" class="custom-control-input" value="Stroke"> 
                                       <span class="custom-control-indicator"></span> 
                                       <span class="custom-control-description">Stroke</span>
                                       </label>
                                    </li>
                                    <li class="list-group-item"><label for="depression" class="comotype custom-control custom-checkbox">
                                       <input type="checkbox" name="comorbidity" id="depression" class="custom-control-input" value="Depression"> 
                                       <span class="custom-control-indicator"></span> 
                                       <span class="custom-control-description">Depression</span>
                                       </label>
                                    </li>
                                 </ul>
                              </div>
                           </div>
                           <div class="col-md-6">
                              <div class="card">
                                 <ul class="list-group list-group-flush">
                                    <li class="list-group-item"><label for="diabetes" class="custom-control custom-checkbox">
                                       <input type="checkbox" name="comorbidity" id="diabetes" class="comotype custom-control-input" value="Diabetes"> 
                                       <span class="custom-control-indicator"></span> 
                                       <span class="custom-control-description">Diabetes</span>
                                       </label>
                                    </li>
                                    <li class="list-group-item"><label for="asthma" class="custom-control custom-checkbox">
                                       <input type="checkbox" name="comorbidity" id="asthma" class="comotype custom-control-input" value="Asthma"> 
                                       <span class="custom-control-indicator"></span> 
                                       <span class="custom-control-description">Asthma</span>
                                       </label>
                                    </li>
                                    <li class="list-group-item"><label for="copd" class="comotype custom-control custom-checkbox">
                                       <input type="checkbox" name="comorbidity" id="copd" class="custom-control-input" value="COPD"> 
                                       <span class="custom-control-indicator"></span> 
                                       <span class="custom-control-description">COPD</span>
                                       </label>
                                    </li>
                                    <li class="list-group-item"><label for="ckd" class="comotype custom-control custom-checkbox">
                                       <input type="checkbox" name="comorbidity" id="ckd" class="custom-control-input" value="Chronic kidney disease (CKD)"> 
                                       <span class="custom-control-indicator"></span> 
                                       <span class="custom-control-description">Chronic kidney disease (CKD)</span>
                                       </label>
                                    </li>
                                    <li class="list-group-item"><label for="dementia" class="comotype custom-control custom-checkbox">
                                       <input type="checkbox" name="comorbidity" id="dementia" class="custom-control-input" value="Dementia"> 
                                       <span class="custom-control-indicator"></span> 
                                       <span class="custom-control-description">Dementia</span>
                                       </label>
                                    </li>
                                 </ul>
                              </div>
                           </div>
                        </div>
                           <!-- <button type="button" data-dismiss="modal" aria-label="Close" class="not-ticked close btn"style=""></button> -->

                           <button type="button" class="btn showalg not-ticked" data-dismiss="modal" aria-label="Close" style="cursor: pointer; opacity: 1;pointer-events: all; margin-top: 1rem">NO COMORBIDITIES TO ADD</button>

                           <button id="showalg" type="button" data-dismiss="modal" class="btn showalg ticked hide" style="cursor: pointer; opacity: 1;pointer-events: all; margin-top: 1rem">Show treatment algorithm</button>
                           
                        <p style="margin-top: 1rem;">Please remember that treatment regimes may change for comorbidities not yet covered by this list.</p>
                     </div>
                     <!-- <div class="modal-footer">
                        <button type="button" class="btn btn-secondary" data-dismiss="modal">Show treatment algorithm</button>
                        <br />Please remember that treatment regimes may change for comorbidities not yet covered by this list.
                        </div> -->
                  </div>
               </div>
            </div>
         <div id="feedbackSuccess" class="modal fade" tabindex="-1" role="dialog" aria-labelledby="ModalFeedbackConfirmedLabel" aria-hidden="true">
            <div class="modal-dialog modal-lg" role="document">
               <div class="modal-content pb-3">
                  <div class="modal-body">
                     <div class="row">
                        <div class="col-md-12">
                           <h2>Thank you</h2>
                           <button type="button" class="close" data-dismiss="modal" aria-label="Close">
                           <span aria-hidden="true">×</span>
                           </button>
                        </div>
                     </div>
                     <div class="row">
                        <div class="col-md-12">
                           <p>Your feedback has been submitted successfully.</p>
                        </div>
                     </div>
                  </div>
               </div>
            </div>
         </div>
         <div id="feedBackBtn">
            <p role="button"><a href="https://bestpractice.bmj.com/topics/en-gb/116/treatment-algorithm#"><span class="material-icons"></span>&nbsp;FEEDBACK</a></p>
         </div>
      </div>
      <script type="text/javascript" src="../js/common.js"></script>
      <script type="text/javascript" src="../js/main.js"></script>
      <script>
         // Code for the recently viewed topics suggestion, needs to be inlined to use the Java values
         /*<![CDATA[*/       
         function dedupe(array) {
           var seen = {};
           return array.filter(function(item) {
               return seen.hasOwnProperty(item.id) ? false : (seen[item.id] = true);
           });
         }
         function TopicViewed(id, title, lang) {
           this.id = id;
           this.title = title;
           this.lang = lang;
         }
         jQuery(document).ready(function() {
           var topicId = 116;
           var topicLang = "en-gb";
           var topicTitle = "Pulmonary embolism";
           if(topicId){
               
             var topicsViewed = [];
             if (localStorage.getItem("topicsViewed") !== null) {
               topicsViewed = JSON.parse(localStorage.topicsViewed);
             }
               
             topicsViewed.unshift(new TopicViewed(topicId, topicTitle, topicLang));// Add new topics at the beginning
             topicsViewed = dedupe(topicsViewed);// Remove duplicates
             if (topicsViewed.length > 15){// Drop if size is bigger than 15
               topicsViewed = topicsViewed.slice(0,14);  
             }
         
             localStorage.topicsViewed = JSON.stringify(topicsViewed);
           }
          });       
         /*]]>*/
      </script>
      
   </body>
</html>